<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53111</article-id><article-id pub-id-type="doi">10.7554/eLife.53111</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-162706"><name><surname>Sampson</surname><given-names>Timothy R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2486-8766</contrib-id><email>trsamps@emory.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-163047"><name><surname>Challis</surname><given-names>Collin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-163048"><name><surname>Jain</surname><given-names>Neha</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/><xref ref-type="fn" rid="pa2">§</xref></contrib><contrib contrib-type="author" id="author-163049"><name><surname>Moiseyenko</surname><given-names>Anastasiya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-10039"><name><surname>Ladinsky</surname><given-names>Mark S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-163052"><name><surname>Shastri</surname><given-names>Gauri G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-163053"><name><surname>Thron</surname><given-names>Taren</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-163054"><name><surname>Needham</surname><given-names>Brittany D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-163055"><name><surname>Horvath</surname><given-names>Istvan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-163056"><name><surname>Debelius</surname><given-names>Justine W</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/><xref ref-type="fn" rid="pa3">#</xref></contrib><contrib contrib-type="author" id="author-163057"><name><surname>Janssen</surname><given-names>Stefan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0955-0589</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/><xref ref-type="fn" rid="pa4">¶</xref></contrib><contrib contrib-type="author" id="author-31673"><name><surname>Knight</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-163058"><name><surname>Wittung-Stafshede</surname><given-names>Pernilla</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1058-1964</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-60409"><name><surname>Gradinaru</surname><given-names>Viviana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5868-348X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-98644"><name><surname>Chapman</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-13814"><name><surname>Mazmanian</surname><given-names>Sarkis K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2713-1513</contrib-id><email>sarkis@caltech.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Division of Biology &amp; Biological Engineering</institution><institution>California Institute of Technology</institution><addr-line><named-content content-type="city">Pasadena</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Molecular, Cellular, and Developmental Biology</institution><institution>University of Michigan</institution><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Biology and Biological Engineering</institution><institution>Chalmers University of Technology</institution><addr-line><named-content content-type="city">Gothenburg</named-content></addr-line><country>Sweden</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Pediatrics</institution><institution>University of California, San Diego</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Computer Science and Engineering</institution><institution>University of California, San Diego</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chiu</surname><given-names>Isaac M</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Garrett</surname><given-names>Wendy S</given-names></name><role>Senior Editor</role><aff><institution>Harvard T.H. Chan School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Department of Physiology, Emory University School of Medicine, Atlanta, United States</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Department of Bioscience and Bioengineering, Indian Institute of Technology, Jodhpur, India</p></fn><fn fn-type="present-address" id="pa3"><label>#</label><p>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden</p></fn><fn fn-type="present-address" id="pa4"><label>¶</label><p>Algorithmic Bioinformatics, Justus-Liebig-University Giessen, Giessen, Germany</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>11</day><month>02</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e53111</elocation-id><history><date date-type="received" iso-8601-date="2019-10-28"><day>28</day><month>10</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-01-23"><day>23</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Sampson et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Sampson et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53111-v1.pdf"/><abstract><p>Amyloids are a class of protein with unique self-aggregation properties, and their aberrant accumulation can lead to cellular dysfunctions associated with neurodegenerative diseases. While genetic and environmental factors can influence amyloid formation, molecular triggers and/or facilitators are not well defined. Growing evidence suggests that non-identical amyloid proteins may accelerate reciprocal amyloid aggregation in a prion-like fashion. While humans encode ~30 amyloidogenic proteins, the gut microbiome also produces functional amyloids. For example, curli are cell surface amyloid proteins abundantly expressed by certain gut bacteria. In mice overexpressing the human amyloid α-synuclein (αSyn), we reveal that colonization with curli-producing <italic>Escherichia coli</italic> promotes αSyn pathology in the gut and the brain. Curli expression is required for <italic>E. coli</italic> to exacerbate αSyn-induced behavioral deficits, including intestinal and motor impairments. Purified curli subunits accelerate αSyn aggregation in biochemical assays, while oral treatment of mice with a gut-restricted amyloid inhibitor prevents curli-mediated acceleration of pathology and behavioral abnormalities. We propose that exposure to microbial amyloids in the gastrointestinal tract can accelerate αSyn aggregation and disease in the gut and the brain.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>microbiome</kwd><kwd>alpha-synuclein</kwd><kwd>Curli</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001167</institution-id><institution>Larry L. Hillblom Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sampson</surname><given-names>Timothy R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014221</institution-id><institution>Heritage Medical Research Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Gradinaru</surname><given-names>Viviana</given-names></name><name><surname>Mazmanian</surname><given-names>Sarkis K</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wittung-Stafshede</surname><given-names>Pernilla</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Swedish Research Council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wittung-Stafshede</surname><given-names>Pernilla</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG054101</award-id><principal-award-recipient><name><surname>Challis</surname><given-names>Collin</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM118651</award-id><principal-award-recipient><name><surname>Chapman</surname><given-names>Matthew</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>NS085910</award-id><principal-award-recipient><name><surname>Mazmanian</surname><given-names>Sarkis K</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>Department of Defense</institution></institution-wrap></funding-source><award-id>PD160030</award-id><principal-award-recipient><name><surname>Mazmanian</surname><given-names>Sarkis K</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Axial Biotherapeutics</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mazmanian</surname><given-names>Sarkis K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Production of an amyloid protein by bacteria within the gut microbiome can influence the pathophysiology of a mouse model of synucleinopathy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The accumulation and aggregation of amyloid proteins occurs during many neurodegenerative diseases. Synucleinopathies are one family of amyloid disease, which includes Parkinson’s disease (PD), Lewy Body disease (LBD), and Multiple System Atrophy (MSA). Central to their pathogenesis is the accumulation of the neuronal protein α-Synuclein (αSyn) into insoluble amyloid aggregations, which ultimately leads to inflammation and neuronal dysfunction (<xref ref-type="bibr" rid="bib32">Jucker and Walker, 2013</xref>; <xref ref-type="bibr" rid="bib6">Brettschneider et al., 2015</xref>). αSyn aggregation can contribute to the death of dopaminergic neurons in specific brain regions, resulting in motor symptoms (<xref ref-type="bibr" rid="bib55">Poewe et al., 2017</xref>). Clinical and epidemiological data suggest that accumulation of αSyn aggregates may first occur at peripheral sites, such as the olfactory epithelium or gastrointestinal (GI) tract, before spreading to the brain (<xref ref-type="bibr" rid="bib5">Braak et al., 2003</xref>). Individuals diagnosed with various synucleinopathies often display constipation and other GI dysfunctions years prior to the onset of movement dysfunction (<xref ref-type="bibr" rid="bib73">Verbaan et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Colosimo, 2011</xref>; <xref ref-type="bibr" rid="bib16">Engen et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Mertsalmi et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Sakakibara et al., 2019</xref>). Experimental evidence exists for a prion-like spread of αSyn aggregates (<xref ref-type="bibr" rid="bib78">Woerman et al., 2015</xref>), including propagation from the gut to the brain via the vagus nerve and/or spinal cord in rodent models (<xref ref-type="bibr" rid="bib28">Holmqvist et al., 2014</xref>; <xref ref-type="bibr" rid="bib70">Uemura et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Van Den Berge et al., 2019</xref>). In humans, recent epidemiological studies suggest an association between truncal vagotomy and appendectomy with a decreased risk of PD (<xref ref-type="bibr" rid="bib67">Svensson et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Killinger et al., 2018</xref>), and in increased risk of comorbidity with inflammatory bowel disease (IBD) (<xref ref-type="bibr" rid="bib30">Hui et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Peter et al., 2018</xref>). While a role for protein aggregation and/or inflammation in the gut represents an emerging area of research in synucleinopathies, the GI tract has been implicated in other neurological disorders such as autism spectrum disorder, depression, anxiety and Alzheimer’s disease (<xref ref-type="bibr" rid="bib75">Vuong et al., 2017</xref>).</p><p>The gut is colonized with a complex microbiome that impacts development and function of the immune, metabolic and nervous systems (<xref ref-type="bibr" rid="bib22">Fung et al., 2017</xref>). Enterobacteriaceae, highly prevalent within the gut of humans, can produce functional amyloid proteins termed curli (<xref ref-type="bibr" rid="bib69">Tursi and Tükel, 2018</xref>). Curli fibers are formed by bacterial secretion of an unfolded amyloid, CsgA, that subsequently aggregates extracellularly to form biofilms, mediate adhesion to epithelial cells, and are involved in bacteriophage defense (<xref ref-type="bibr" rid="bib69">Tursi and Tükel, 2018</xref>; <xref ref-type="bibr" rid="bib74">Vidakovic et al., 2018</xref>). Exposure to curli not only modulates host inflammatory responses within the intestinal tract and periphery (<xref ref-type="bibr" rid="bib23">Gallo et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Tursi and Tükel, 2018</xref>), but oral administration of curli-producing bacteria can also increase production and aggregation of the amyloid protein αSyn in aged rats and nematodes (<xref ref-type="bibr" rid="bib8">Chen et al., 2016</xref>). Biochemical studies demonstrate that native, bacterial chaperones of curli are capable of transiently interacting with αSyn and modulating its aggregation (<xref ref-type="bibr" rid="bib11">Chorell et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Evans et al., 2015</xref>). Interestingly, diverse human amyloid proteins including αSyn, amyloid beta (Aβ), cellular prion protein (PrP<sup>C</sup>), and Tau can accelerate the amyloidogenesis of heterologous mammalian amyloid proteins (<xref ref-type="bibr" rid="bib13">Clinton et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Brettschneider et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Katorcha et al., 2017</xref>). Lesions containing mixed human amyloids have been observed in neurodegenerative brains (<xref ref-type="bibr" rid="bib56">Rahimi and Kovacs, 2014</xref>; <xref ref-type="bibr" rid="bib65">Spires-Jones et al., 2017</xref>), implicating interactions between different amyloidogenic proteins in resulting pathology. Accordingly, we wondered whether a bacterial amyloid protein can contribute to heterologous aggregation of mammalian αSyn in the gut and the brain, leading to synucleinopathy-related behaviors.</p><p>Herein, we reveal that mono-colonization of αSyn-overexpressing mice with curli-producing <italic>Escherichia coli</italic> exacerbates motor impairment and GI dysfunction, and promotes αSyn aggregation and inflammation in the gut and brain. Enrichment of curli-producing <italic>E. coli</italic> to mice harboring a healthy human microbiome is sufficient to aggravate αSyn-dependent pathophysiology. The purified amyloidogenic subunit of curli fibers (CsgA) is sufficient to accelerate αSyn aggregation during in vitro biochemical assays and pathophysiology in mice following intra-intestinal administration, while variants of CsgA that are unable to form amyloids have no effect on αSyn aggregation. Oral treatment of mice with a gut-restricted amyloid inhibitor reduces <italic>csgA</italic> expression in the gut, limits αSyn aggregation in the brain, and alleviates GI and motor deficits in mice that overexpress αSyn. These data provide novel insights into a trans-kingdom interaction between the gut microbiome and mammalian amyloids, and suggest the possibility that carriage of particular bacterial taxa may be a factor that can exacerbate neurologic disease.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Mono-colonization with curli-producing gut bacteria enhances αSyn pathophysiology</title><p>We previously identified that depletion of the microbiome reduces pathophysiology in Thy1-αSyn mice (<italic>a</italic>lpha-<italic>s</italic>ynuclein <italic>o</italic>verexpressing; ASO mice) (<xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>), which overexpress wild-type human αSyn. Due to accumulation and aggregation of neuronal αSyn, mice display increased neuroinflammation, GI dysfunction, and progressive motor abnormalities (<xref ref-type="bibr" rid="bib58">Rockenstein et al., 2002</xref>; <xref ref-type="bibr" rid="bib9">Chesselet et al., 2012</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2012</xref>) that are relevant in the study of synucleinopathies. Prior findings in germ-free Thy1-αSyn mice suggest that an unidentified member(s) of the gut microbiome may be pathogenic in this mouse model (<xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>). Interestingly, increased colonization and mucosal association with Enterobacteriaceae, such as <italic>E. coli</italic>, have been reported in individuals with PD compared to healthy controls (<xref ref-type="bibr" rid="bib20">Forsyth et al., 2011</xref>), as well as a positive association of Enterobacteriaceae abundance with disease severity (<xref ref-type="bibr" rid="bib62">Scheperjans et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Li et al., 2017</xref>).</p><p>To establish whether <italic>E. coli</italic> promotes αSyn-dependent motor dysfunction, we mono-associated germ-free (GF) wild-type and ASO mice with the curli-producing <italic>E. coli</italic> strain MC4100, or <italic>Bacteroides fragilis</italic> strain NCTC9343 and segmented filamentous bacteria (SFB), which do not produce curli. <italic>E. coli</italic> exacerbated the αSyn-dependent motor defects in ASO animals across a battery of tests, compared to the other taxa (<xref ref-type="fig" rid="fig1">Figure 1A–F</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–E</xref>). To determine the contribution of curli amyloids, we compared mice mono-colonized with wild-type <italic>E. coli</italic> (WT) to those mono-colonized with an isogenic mutant lacking genes encoding the curli biosynthesis machinery (Δ<italic>csgBAC</italic>) (<xref ref-type="bibr" rid="bib77">Wang and Chapman, 2008</xref>). Evaluation of coordinated motor function revealed that colonization with the curli-deficient strain did not elicit robust motor impairment (<xref ref-type="fig" rid="fig1">Figure 1A–F</xref>). We did not observe curli-dependent alterations to colonization levels or mucosal association, despite detecting <italic>csgA</italic> expression (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–I</xref>). In addition, the curli-deficient mutant did not display alterations to lipopolysaccharide potency or structure (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1J,K</xref>). Thus, curli-producing bacteria are capable of enhancing motor deficits in ASO mice.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Mono-colonization with curli-producing gut bacteria enhances αSyn pathophysiology germ-free wild-type BDF1 (WT) and Thy1-αSyn (ASO) mice were mono-colonized with wild-type <italic>E. coli</italic> MC4100 (WT) or an isogenic curli-deficient strain (Δ<italic>csgBAC</italic>) at 5–6 weeks of age.</title><p>Motor function was assessed at 12–13 weeks of age by quantifying (<bold>A</bold>), beam traversal time, (<bold>B</bold>), pole descent time, (<bold>C</bold>), nasal adhesive removal time, (<bold>D</bold>), hindlimb clasping score, (<bold>E</bold>), wirehang time. (<bold>F</bold>), Principal component analysis of compiled motor scores from tests in (<bold>A–E</bold>). Quantification of (<bold>G, H</bold>) pS129αSyn and (<bold>I</bold>) proteinase K–resistant αSyn by immunofluorescence microscopy in the substantia nigra and midbrain. n = 13–16 (<bold>A–F</bold>), n = 4.5 (<bold>G–I</bold>). Points represent individuals, bars represent the mean and standard error. Data analyzed by one-way ANOVA with Tukey post-hoc test (<bold>A–E</bold>), and two-tailed <italic>t-</italic>test for (<bold>G–I</bold>). *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. Motor data are compiled from three independent cohorts.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>E. coli</italic> alters motor deficits, and CsgA does not influence colonization, inflammatory capacity, or dopamine production Germ-free (GF) wild-type (WT) or Thy1- αSyn (ASO) mice were mono-colonized with either <italic>Bacteroides fragilis</italic> (Bfrag), segmented filamentous bacteria (SFB), or <italic>Escherichia coli</italic> (Ecoli).</title><p>Motor function assessed by (<bold>A</bold>) beam crossing time, (<bold>B</bold>) pole descent time, (<bold>C</bold>) adhesive removal time, or <bold>D</bold>) hindlimb reflex score.( <bold>E,</bold>) PCA analysis of scores in (<bold>A–D</bold>). (<bold>F–N</bold>) GF WT and ASO mice were mono-colonized with curli-sufficient <italic>E. coli</italic> (WT) or curli-deficient <italic>E. coli</italic> (Δ<italic>csgBAC</italic>). (<bold>F</bold>) Fecal bacterial burden determined by plate culture. (<bold>G</bold>) Bacterial burden of tissue/mucus fractions and luminal fractions of proximal colon. (<bold>H</bold>) <italic>csgA</italic> expression within fecal contents determined by qRT-PCR. (<bold>I</bold>) Representative TEM of bacterial localization in the proximal colon. 1- Bacteria, 2-mucus layer, 3-glycocalyx. (<bold>J</bold>) Quantification of endotoxin as determined by LAL assay. (<bold>K</bold>) Pro-Q Emerald stain (LPS) of SDS-PAGE separated cell lysates, Ldr- ladder, Std- LPS standard, WT- wild-type, Δcsg- <italic>ΔcsgBAC</italic>. n = 7–14 (<bold>A–E</bold>); n = 7–9 (<bold>F, H</bold>); n = 3 (<bold>G</bold>). Points represent individuals, bars represent the mean and standard error. Data analyzed by one-way ANOVA with Tukey post-hoc test (<bold>A–D</bold>). *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. In (<bold>A–D</bold>), data are compiled from two independent cohorts for <italic>B. fragilis</italic> and SFB, compared to <italic>E. coli</italic> mono-colonized cohorts used in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Mono-colonization with curli-sufficient bacteria induce increased αSyn-dependent pathology Germ-free (GF) wild-type (WT) or Thy1-αSyn (ASO) animals were mono-colonized with curli-sufficient <italic>E. coli</italic> (WT) or curli-deficient <italic>E. coli</italic> (Δ<italic>csgBAC</italic>).</title><p>(<bold>A</bold>) Total αSyn in whole brain lysates quantified by ELISA. Quantification of insoluble αSyn fibrils in the (<bold>B</bold>) striatum and (<bold>C</bold>) midbrain by dot blot assay. Midbrain homogenates of ASO animals were (<bold>D</bold>) fractionated with Triton X-100 and SDS-PAGE, and subsequently probed for alpha-synuclein (αSyn) via western blot, or (<bold>E</bold>) left unfractionated and assessed by western blot for phospho-Serine129 αSyn (pS129). (<bold>F–H</bold>) Quantification of western blots by integrated density. Representative images from of mono-colonized ASO mice of the (<bold>I</bold>) midbrain stained for proteinase K-resistant αSyn (green), (<bold>J</bold>) substantia nigra stained for tyrosine hydroxylase (TH, green) and pS129 (red), and (<bold>K</bold>) frontal cortex stained for pS129 (red) and quantified in (<bold>L</bold>). (<bold>M</bold>) Representative images of the myenteric plexus within proximal large intestine of mono-colonized ASO animals stained for PGP9.5 (white) and pS129αSyn (green,), and counts of PGP9.5+ cells bodies per ganglia. (<bold>N</bold>) Proximal large intestine homogenates of mono-colonized ASO animals were assessed by SDS-PAGE and analyzed by western blot for pS129αSyn. Quantification of insoluble αSyn fibrils in the (<bold>O</bold>) duodenum and (<bold>P</bold>) proximal large intestine by dot blot assay. (<bold>Q</bold>) Total striatal dopamine quantified by ELISA. (<bold>R</bold>) <italic>TH</italic> expression in the midbrain by qPCR. (<bold>S</bold>) Quantification of TH+ cells in representative sections of the SN. n = 3 (<bold>A–H, L</bold>), n = 4 (<bold>O, P</bold>), n = 7–9 (<bold>Q</bold>), n = 3–4 (<bold>R</bold>), n = 4–5 (<bold>S</bold>). Full-length immunoblots available in associated Source Data file. Points represent individuals, bars represent the mean and standard error. Data analyzed by one-way ANOVA with Tukey post-hoc test for <bold>A-C, Q</bold>, or two-tailed <italic>t</italic>-test for <bold>F-H, L, O, P, R, S</bold>. *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. Scale bars = 100 μm.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Mono-colonization with curli-sufficient bacteria induces altered inflammatory responses in the brain and intestine.</title><p>Germ-free (GF) wild-type (WT) or Thy1-αSyn (ASO) animals were mono-colonized with either wild-type, curli-sufficient <italic>E. coli</italic> (WT) or curli-deficient <italic>E. coli</italic> (Δ<italic>csgBAC</italic>). Quantification of IL-6 and TNFα by ELISA from homogenates derived from the (<bold>A</bold>) midbrain or (<bold>B</bold>) striatum. (<bold>C</bold>) CD11b<sup>+</sup> cells enriched from total brains and gene expression of <italic>il6</italic> and <italic>tnfa</italic> quantified by qRT-PCR, relative to <italic>gapdh</italic>. Representative thin sections of (<bold>D</bold>) substantia nigra and (<bold>F</bold>) striatum derived from ASO mice stained for Iba1 (microglia). 3D cellular reconstructions of microglia generated and morphological characteristics quantified of (<bold>E</bold>) substantia nigra- and (<bold>G</bold>) striatum—resident microglia. Multiplex ELISA performed for cytokines and chemokines derived from (<bold>H</bold>) homogenates derived from proximal large intestine tissue of indicated animals or (<bold>I</bold>) serum of ASO animals. Quantification of IL-6 and IL-17 by ELISA from tissue homogenates of the (<bold>J</bold>) proximal large intestine or (<bold>K</bold>) duodenum derived from ASO animals. n = 6–7 (<bold>A–C</bold>), n = 4 (<bold>D–G</bold>) (averaged from 20 to 40 cells for diameters, or 5–7 cells for branching), n = 3 (<bold>H</bold>), n = 4–5 (<bold>J, K</bold>). Points represent individuals, bars represent the mean and standard error. Data analyzed by one-way ANOVA with Tukey post-hoc test for <bold>A–C</bold>), or two-tailed <italic>t</italic>-test for <bold>E, J</bold>) and <bold>K</bold>). *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. Scale bars = 100 μm.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig1-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig1-figsupp3-v1.tif"/></fig></fig-group><p>ASO mice colonized with curli-producing bacteria displayed increased αSyn fibril reactivity and detergent-insoluble αSyn in the midbrain compared to mice with the Δ<italic>csgBAC</italic> strain, despite similar transgene production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 2A–D,F,G</xref>). Histological and western blot analysis revealed increased phospho-serine129 αSyn (pS129-αSyn) deposition in the substantia nigra (SN) of ASO mice, indicative of pathological αSyn aggregation, (<xref ref-type="fig" rid="fig1">Figure 1G,H</xref>, and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E,H,J</xref>). Further, mice colonized with WT <italic>E. coli</italic> show increased proteinase K-resistant αSyn inclusions in the midbrain (<xref ref-type="fig" rid="fig1">Figure 1I</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2I</xref>), with little alteration to pS129-αSyn in the frontal cortex (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2K,L</xref>). Additionally, we observed increased pS129-αSyn in the proximal large intestine, and elevated αSyn fibril reactivity in the duodenum and proximal large intestine of ASO mice mono-colonized with curli-producing <italic>E. coli</italic> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 2M–P</xref>). Previous research has shown that synuclein pathology, neuroinflammation, and motor defects occur at early ages in the ASO mouse model without concomitant loss of striatal dopamine, tyrosine hydroxylase positive (TH<sup>+</sup>) neurons in the midbrain, or loss of neurons in the myenteric plexus (<xref ref-type="bibr" rid="bib19">Fleming et al., 2004</xref>; <xref ref-type="bibr" rid="bib40">Lam et al., 2011</xref>; <xref ref-type="bibr" rid="bib9">Chesselet et al., 2012</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2012</xref>). Consistent with these prior observations, we do not observe decreases in total striatal dopamine, midbrain <italic>TH</italic> expression, TH<sup>+</sup> neurons, nor myenteric PGP9.5<sup>+</sup> neurons, under the colonization conditions and ages assessed, suggesting pathology and motor deficits are independent of dopamine or neuron loss (<xref ref-type="fig" rid="fig1">Figure 1</xref>, figure supplement S2Q-S).</p><p>Mono-colonization of ASO mice with curli-producing <italic>E. coli</italic> resulted in increased expression of the proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα) in brain-derived CD11b<sup>+</sup> cells, and increased cytokine production in the midbrain and striatum (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 3A–C</xref>). In addition, Iba<sup>+</sup> microglia morphologies indicated reduced activation in ASO mice colonized with the curli-deficient strain (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 3D–G</xref>). Multiplexed ELISA analysis revealed increased cytokine and chemokine production in colonic tissue of mice mono-colonized with curli-producing <italic>E. coli</italic>, irrespective of genotype (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3H,J,K</xref>), and no noteworthy changes to serum cytokines of ASO mice based on colonization status (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3I</xref>). These data reveal that a bacterial amyloid from the gut microbiome can exacerbate pathology and inflammation, in both the gut and brain, in mice that overexpress αSyn.</p></sec><sec id="s2-2"><title>Curli biosynthesis within a complex microbiome contributes to motor and GI deficits</title><p>To explore host-microbiome interactions in a more natural context, we tested whether introduction of curli-producing bacteria to a healthy human microbiota is sufficient to enhance αSyn-dependent pathophysiology. GF ASO mice were transplanted with fecal microbiota from a human donor predicted to contain low levels of <italic>csgA</italic>, as indicated by PICRUSt analysis following 16S rRNA sequencing (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). This single microbiome was supplemented with either WT <italic>E. coli</italic> or the Δ<italic>csgBAC</italic> strain. Both strains reached similar abundances in the feces (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B,C</xref>), while <italic>csgA</italic> expression and amyloid production appeared only in mice colonized with WT bacteria (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–E</xref>). Mice harboring a microbiota containing WT <italic>E. coli</italic> displayed significantly impaired motor and GI performance compared to animals with a complex microbiota plus the curli-deficient strain (<xref ref-type="fig" rid="fig2">Figure 2A–G</xref>). Moreover, enrichment of curli-producing bacteria resulted in increased αSyn fibril reactivity in the midbrain and elevated pS129-αSyn deposition in the SN, without changes to the number of TH<sup>+</sup> neurons (<xref ref-type="fig" rid="fig2">Figure 2H</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F–J</xref>). Morphometric analysis of microglia demonstrated concomitant changes indicative of inflammatory status in the midbrain (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1K–N</xref>). Therefore, in the context of a complex human microbiota, curli-producing <italic>E. coli</italic> are sufficient to modulate αSyn-mediated pathophysiology.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Curli biosynthesis within a complex microbiome contributes to motor and GI deficits Germ-free Thy1-αSyn (ASO) mice were colonized with fecal microbes derived from healthy human at 5–6 weeks of age, and concurrently supplemented with either wild-type <italic>E. coli</italic> MC4100 (+WT) or a curli-deficient strain (+Δ<italic>csgBAC</italic>).</title><p>Motor function was tested longitudinally at 12, 15, and 20 weeks of age in the (<bold>A</bold>) beam traversal, (<bold>B</bold>) pole descent, (<bold>C</bold>) adhesive removal, (<bold>D</bold>) hindlimb clasping score, (<bold>E</bold>) wirehang tests. (<bold>F</bold>) Principal component analysis of compiled motor scores from tests in (<bold>A–E</bold>). (<bold>G</bold>) Fecal output over a 15-min period observed at week 21 of age. Quantification of (<bold>H</bold>) pS129αSyn by immunofluorescence microscopy in the substantia nigra. n = 12 (<bold>A–F</bold>), n = 6 (<bold>G</bold>), n = 4 (<bold>H</bold>). Data points represent individuals, bars represent the mean and standard error. Time courses analyzed by two-way ANOVA, with Sidak post-hoc test for between group comparisons indicated above individual time points, and brackets indicating significance between colonization status. Data in (<bold>H</bold>) analyzed two-tailed <italic>t-</italic>test. *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. Motor data are compiled from two independent cohorts.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Amyloid-producing bacteria in humanized animals modulate microglia responses.</title><p>(<bold>A</bold>) Human samples from previous cohort (ENA Accession: PRJEB17694) were analyzed by PICRUSt to infer abundance of <italic>csgA</italic> encoded within each population, arrow indicates sample utilized for transplantation. Fecal pellets of Thy1-αSyn (ASO) mice receiving healthy-human derived fecal microbes enriched with either wild-type, curli-sufficient <italic>E. coli</italic> (WT) or curli-deficient <italic>E. coli</italic> (Δ<italic>csgBAC</italic>) were analyzed by (<bold>B</bold>) qPCR for <italic>rrsA</italic> abundance relative to 16 s rRNA present in fecal bacterial DNA and ratios of (<bold>C</bold>) YESCA/blood agar aerobic colony forming units and (<bold>D</bold>) congo red-positive/blood agar colony forming units calculated. (<bold>E</bold>) qPCR analysis for <italic>csgA</italic> expression relative to <italic>rrsA</italic> in fecal bacterial RNA. (<bold>F</bold>) Representative images of the substantia nigra in humanized ASO mice stained for TH (green) and pS129 (red) and quantified in (<bold>G, H</bold>). Quantification of insoluble αSyn fibrils in the (<bold>I</bold>) midbrain and (<bold>J</bold>) striatum by dot blot assay. Representative thin sections of (<bold>K</bold>) substantia nigra and (<bold>M</bold>) striatum derived from ASO mice stained for Iba1 (microglia; red). 3D cellular reconstructions of microglia generated and morphological characteristics quantified of (<bold>L</bold>) substantia nigra- and (<bold>N</bold>) striatum—resident microglia. n = 5 (<bold>A</bold>), n = 8 (<bold>B, E</bold>), n = 4 (<bold>C–J</bold>), n = 3 (<bold>K–N</bold>) (averaged from 20 to 40 cells for diameters, or 5–7 cells for branching) Points represent individuals, bars represent the mean and standard error. Data in (<bold>B, E, I</bold>) analyzed by two-tailed Mann-Whitney test or t-test in <bold>L</bold>. *p≤0.05; ***p≤0.001. Scale bars = 100 μm.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>The bacterial amyloid protein, CsgA, accelerates αSyn fibrilization</title><p>Emerging data suggest that non-orthologous amyloid proteins can accelerate heterologous aggregation (<xref ref-type="bibr" rid="bib13">Clinton et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Brettschneider et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Katorcha et al., 2017</xref>). We therefore tested whether CsgA can directly impact aggregation of αSyn. Purified monomeric CsgA accelerated production of αSyn aggregates during in vitro biochemical amyloid assays (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), even at concentrations below which CsgA self-aggregates (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The αSyn fibrils purified from these reactions maintained an ability to accelerate αSyn amyloidogenesis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B,C</xref>), suggesting that CsgA-induced αSyn aggregates are propagation-competent, similar to other amyloids (<xref ref-type="bibr" rid="bib65">Spires-Jones et al., 2017</xref>). Surprisingly, we could not detect a direct interaction between purified CsgA and αSyn monomers by surface plasmon resonance (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), perhaps indicating transient interactions or requirements for prior oligomerization of either or both proteins. Unlike αSyn, Tau aggregation was not accelerated by CsgA (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–G</xref>). Native amyloid-forming properties of CsgA are required, as a non-amyloidogenic form of CsgA (CsgA:Q49A/N54A/Q139A/N144A; ‘SlowGo’ <xref ref-type="bibr" rid="bib77">Wang and Chapman, 2008</xref>) did not augment αSyn aggregation in vitro (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–C</xref>). To investigate the dependence of these amyloidogenic residues in vivo, we mono-colonized ASO mice with <italic>E. coli</italic> producing either wild-type CsgA or CsgA:SlowGo proteins (<xref ref-type="bibr" rid="bib77">Wang and Chapman, 2008</xref>). Motor performance in ASO mice harboring SlowGo-producing <italic>E. coli</italic> was less severe in comparison to mice colonized with WT bacteria (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D–H</xref>), although not to the extent of the Δ<italic>csgBAC</italic> strain, qualitatively (see <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The bacterial amyloid protein, CsgA, accelerates αSyn fibrilization In vitro biophysical analysis with purified αSyn and CsgA proteins.</title><p>(<bold>A</bold>) Aggregation as measured by Thioflavin T fluorescence over time during αSyn amyloid formation alone or in the presence of CsgA monomers (25:1 molar ratio). Time to reach (<bold>B</bold>) exponential fibrilization/lag phase and (<bold>C</bold>) half-maximum from reactions in (<bold>A</bold>). (<bold>D</bold>) Representative transmission electron micrographs of αSyn or CsgA alone, or in combination, at 0 and 60 hr post-aggregation. n = 3 (<bold>A–C</bold>). Bars represent the mean and standard error. Data are analyzed by two-tailed, <italic>t-</italic>test. **p≤0.01; ***p≤0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>CsgA seeds αSyn aggregation and propagation in vitro.</title><p>(<bold>A</bold>) Circular dichroism spectroscopic analysis of αSyn fibrilization alone or in the presence of CsgA at 0, 12.5, and 60 hr post-aggregation. (<bold>B</bold>) Thioflavin T fluorescence during αSyn amyloid formation alone or in the presence of 5% seeds previously generated by addition of CsgA monomer to αSyn (as in <xref ref-type="fig" rid="fig2">Figure 2a</xref>) or αSyn alone. (<bold>C</bold>) Transmission electron micrograph of fibril structures generated by the addition of above seeds and of seeds themselves. (<bold>D</bold>) Surface plasmon resonance measurements of surface immobilized αSyn with additions of either CsgA monomer or seeds, or DOPS-DOPG cholesterol liposomes as positive control. (<bold>E</bold>) Amyloid aggregation as measured by Thioflavin T fluorescence with Tau alone or in the presence of CsgA monomers (25:1 molar ratio, red). Time to reach (<bold>F</bold>) exponential fibrilization/lag phase and (<bold>G</bold>) half-maximum from reactions in (<bold>E</bold>).</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>CsgA seeds αSyn aggregation in vitro and in vivo through native amyloidogenic properties.</title><p>(<bold>A</bold>) Amyloid aggregation as measured by Thioflavin T fluorescence with αSyn alone or in the presence of non-amyloidogenic CsgA monomers (SlowGo, 25:1 molar ratio, red). Time to reach (<bold>B</bold>) exponential fibrilization/lag phase and (<bold>C</bold>) half-maximum from reactions in (<bold>A</bold>). (<bold>D–H</bold>) Germ-free Thy1-αSyn mice (ASO) were mono-colonized with <italic>E. coli</italic> producing either wild-type CsgA (WT) or SlowGo (SlowGo), and motor function assessed at 12-13 weeks of age in (<bold>D</bold>) beam traversal, (<bold>E</bold>) pole descent, (<bold>F</bold>) adhesive removal, (<bold>G</bold>) hindlimb reflexes, and (<bold>H</bold>) wirehang. Points represent individuals, bars represent the mean and standard error, n = 10–11 (<bold>D–H</bold>). Data in (<bold>D–H</bold>) analyzed by two-tailed Mann-Whitney test. *p≤0.05; **p≤0.01.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig3-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Intestinal injection of amyloidogenic curli promotes progressive motor dysfunction.</title><p>Conventionally-raised Thy1-αSyn (ASO) mice were injected intestinally with 30 μg of synthetic CsgA hexamer (CsgA; N-QYGGNN-C) or non-amyloidgenic peptide (N122A; N-QYGGNA-C). Motor function assessed overtime at 0, 7, 21, and 70 days post-injection in the (<bold>A</bold>) beam traversal, (<bold>B</bold>) pole descent, (<bold>C</bold>) adhesive removal, (<bold>D</bold>) hindlimb clasping score, and (<bold>E</bold>) wirehang tests. (<bold>F</bold>) Principal component analysis of compiled motor scores of ASO mice. (<bold>G</bold>) Fecal output observed at day 70 in ASO mice. (<bold>H</bold>) Quantification of insoluble αSyn fibrils in the striatum and ventral midbrain by dot blot assay. n = 8 (<bold>A–G</bold>), n = 4 (<bold>H</bold>). Points represent individuals, bars represent the mean and standard error. Time courses analyzed by two-way ANOVA, with Sidak post-hoc test for between group comparisons indicated above individual time points, and brackets indicating significance between treatments. Data in (<bold>H</bold>) analyzed by two-tailed Mann-Whitney test. *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig3-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig3-figsupp3-v1.tif"/></fig></fig-group><p>Next, a peptide spanning the aggregation domain of CsgA or a non-amyloidogenic version (N122A) (<xref ref-type="bibr" rid="bib68">Tükel et al., 2009</xref>) were injected directly into the intestinal wall of SPF ASO mice. Intra-intestinal delivery of amyloidogenic CsgA peptide, but not the mutant peptide, resulted in progressive motor and GI dysfunction (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A–G</xref>). Furthermore, increased αSyn fibrils were detected in the midbrains of amyloidogenic peptide-injected animals (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3H</xref>). We conclude that gut exposure to a bacterial amyloid is sufficient to exacerbate motor deficits and αSyn brain pathology in this mouse model, in a manner dependent on CsgA aggregation.</p></sec><sec id="s2-4"><title>Curli-driven pathophysiology in mice requires functional amyloid formation</title><p>Epigallocatechin gallate (EGCG) is a plant-derived, dietary polyphenol that physically inhibits amyloid formation, including αSyn aggregation (<xref ref-type="bibr" rid="bib3">Bieschke et al., 2010</xref>). EGCG is also capable of blocking CsgA amyloidogenesis and represses <italic>csgA</italic> transcript expression in <italic>E. coli</italic> through activation of specific stress response pathways within the bacterial cell (<xref ref-type="bibr" rid="bib63">Serra et al., 2016</xref>). We reveal here that EGCG treatment did not impair <italic>E. coli</italic> growth in culture, but significantly reduced biofilm formation, a process dependent on the production and assembly of curli (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>) (<xref ref-type="bibr" rid="bib69">Tursi and Tükel, 2018</xref>). Additionally, EGCG also inhibited CsgA-accelerated αSyn amyloid formation during in vitro biochemical aggregation assays (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Notably, EGCG remains largely gut-restricted in rodents and humans and is not readily bioavailable in circulation or brain tissues following oral administration (<xref ref-type="bibr" rid="bib41">Lambert et al., 2003</xref>; <xref ref-type="bibr" rid="bib44">Lin et al., 2007</xref>; <xref ref-type="bibr" rid="bib7">Cai et al., 2018</xref>). Oral treatment of wild-type <italic>E. coli</italic> mono-colonized ASO mice with EGCG did not affect fecal <italic>E. coli</italic> abundance, but resulted in decreased <italic>csgA</italic> production (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Assessment of motor performance revealed that EGCG improved both motor and GI defects exacerbated by curli-producing <italic>E. coli</italic> in ASO mice (<xref ref-type="fig" rid="fig4">Figure 4C–I</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D–I</xref>). In addition, oral EGCG administration reduced αSyn aggregation and pS129-αSyn deposition in both the striatum and midbrain (<xref ref-type="fig" rid="fig4">Figure 4J</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1J–M</xref>). Furthermore, microglia morphological changes were limited in EGCG-treated mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1O–R</xref>). In addition to its ability to directly inhibit aggregation of bacterial and host-derived amyloids, EGCG has antioxidant and anti-inflammatory activities (<xref ref-type="bibr" rid="bib42">Li et al., 2004</xref>) that may also contribute to the rescue of CsgA-accelerated, αSyn-dependent pathophysiology. Collectively, these data reveal that curli is a specific bacterial structure that can accelerate mammalian amyloid aggregation in vitro and in vivo.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Curli-driven pathophysiology in mice requires functional amyloid formation.</title><p>(<bold>A</bold>), Representative in vitro αSyn aggregation measured by Thioflavin T fluorescence during αSyn amyloid formation alone or in the presence of CsgA (25:1 molar ratio), with and without EGCG (50 μM) treatment. (<bold>B–H</bold>) Germ-free Thy1-αSyn mice (ASO) were mono-colonized with WT <italic>E. coli</italic> at 5–6 weeks of age, and given water alone (Vehicle: Veh) or treated with EGCG <italic>ad lib</italic> in drinking water (+EGCG). (<bold>B</bold>) RNA was extracted from fecal pellets and <italic>csgA</italic> expression quantified by qRT-PCR, relative to <italic>rrsA.</italic> Motor function was assessed at 15–16 weeks of age by quantifying (<bold>C</bold>) beam traversal time, (<bold>D</bold>) pole descent time, (<bold>E</bold>) nasal adhesive removal time, (<bold>F</bold>) hindlimb clasping score, (<bold>G</bold>) wirehang tests. (<bold>H</bold>) Principal component analysis of compiled motor scores from tests in (<bold>C–G</bold>). (<bold>I</bold>) Fecal output over a 15 min period. (<bold>J</bold>) Quantification of insoluble αSyn fibrils in the ventral midbrain by dot blot assay. n = 8 (<bold>B</bold>); n = 10–11 (<bold>C–G</bold>); n = 4–5 (<bold>I, J</bold>). Points represent individuals, bars represent the mean and standard error. Data analyzed by two-tailed Mann-Whitney for <bold>B–G</bold>, (<bold>J</bold>) and two-way ANOVA with Sidek’s post-hoc test for <bold>I</bold> with between group comparisons indicated above individual time points, and brackets indicating significance between treatment status. *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. Motor data compiled from two independent cohorts.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Inhibition of functional amyloid formation dampens progressive pathophysiology.</title><p>(<bold>A</bold>) Wild-type <italic>E. coli</italic> was inoculated into brain-heart infusion broth, containing indicated concentrations of EGCG. Cultures were incubated, with orbital shaking and growth was measured by optical density at 600 nm over time. (<bold>B</bold>) Crystal violet staining of wild-type <italic>E. coli</italic> biofilm at 4 days in static culture, with indicated concentrations of epigallocatechin gallate (EGCG); assessed by optical density (OD). (<bold>C–R</bold>) Germ-free ASO mice were mono-colonized with wild-type <italic>E. coli</italic> and treated with water alone (Vehicle, Veh) or given EGCG <italic>ad lib</italic> in drinking water (+EGCG). (<bold>C</bold>) Fecal pellets were cultured on YESCA agar to determine total viable <italic>E. coli</italic>. Motor function was assessed at 10, 12, and 15 weeks of age by quantifying (<bold>D</bold>) beam traversal time, (<bold>E</bold>) pole descent time, (<bold>F</bold>) nasal adhesive removal time, (<bold>G</bold>) hindlimb reflex score, (<bold>H</bold>) wirehang tests. (<bold>I</bold>) Principal component analysis of compiled motor scores. (<bold>J</bold>) Quantification of insoluble αSyn fibrils in the striatum by dot blot assay. (<bold>K</bold>) Representative images of the substantia nigra in humanized ASO mice stained for TH (green) and pS129 (red) and quantified in (<bold>L–N</bold>). Representative thin sections of (<bold>O</bold>) substantia nigra and (<bold>Q</bold>) striatum were stained for Iba1 (microglia; red) and morphological characteristics of (<bold>P</bold>) substantia nigra- and (<bold>r</bold>) striatum-resident microglia quantified. n = 3 (<bold>A, O–R</bold>) (averaged from 20 to 40 cells for diameters, or 5–7 cells for branching); n = 6–7 (<bold>B</bold>); n = 4–5 (<bold>C, J</bold>), n = 10–11 (<bold>D–I</bold>); n = 3–4 (<bold>K–N</bold>). Points represent individuals, bars represent the mean and standard error. Time courses analyzed by two-way ANOVA, with Sidak post-hoc test for between group comparisons indicated above individual time points, and brackets indicating significance between treatments. Data in (<bold>J</bold>) analyzed by two-tailed Mann-Whitney test and (<bold>L, P, R</bold>) analyzed by two-tailed <italic>t-</italic>test. *p≤0.05; **p≤0.01; ****p≤0.0001.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data and statistical analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-53111-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-53111-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Conclusion</title><p>The majority of synucleinopathy incidences are idiopathic, with multifactorial and complex risks that contribute to disease initiation and/or progression (<xref ref-type="bibr" rid="bib57">Ritz et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Soldner et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Johnson et al., 2019</xref>). Our findings reveal that the bacterial amyloid CsgA can accelerate αSyn aggregation and enhance motor abnormalities in mice that are genetically predisposed to αSyn pathology. Curli production in the gut of non-susceptible mice does not impair motor performance at the timepoints examined, suggesting that this microbial trigger is not sufficient, but rather requires additional predisposing factors to promote disease outcomes. Further, inhibiting amyloid formation in the gut correlates with improvements in curli-induced behaviors and pathology. Our study does not reconcile how curli production within the gastrointestinal tract ultimately manifests αSyn aggregation in the brain. Experimental evidence exists for a prion-like spread of αSyn aggregates (<xref ref-type="bibr" rid="bib78">Woerman et al., 2015</xref>), including propagation from the gut to the midbrain via the vagus nerve and/or spinal cord in rodent models (<xref ref-type="bibr" rid="bib70">Uemura et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="bib72">Van Den Berge et al., 2019</xref>), although evidence for sustained propagation from the GI tract to structures outside the brainstem in primates is currently lacking (<xref ref-type="bibr" rid="bib48">Manfredsson et al., 2018</xref>). Epidemiological studies suggest an association between full truncal vagotomy with a decreased risk of PD (<xref ref-type="bibr" rid="bib67">Svensson et al., 2015</xref>). Intriguingly, there appears to be a positive correlation between inflammatory bowel disease and neurodegenerative disease (<xref ref-type="bibr" rid="bib30">Hui et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Peter et al., 2018</xref>). In experimental models, induction of GI inflammation, for instance through LPS or dextran sodium sulfate administration, is sufficient to induce αSyn pathology in the CNS (<xref ref-type="bibr" rid="bib10">Choi et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Kishimoto et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Perez-Pardo et al., 2019</xref>). Aggregates of both CsgA and αSyn are capable of signaling through the innate immune receptor Toll-like receptor 2 (TLR2) leading to increased inflammatory responses (<xref ref-type="bibr" rid="bib68">Tükel et al., 2009</xref>; <xref ref-type="bibr" rid="bib55">Poewe et al., 2017</xref>). In fact, inhibiting TLR2 in αSyn-based mouse models leads to improved pathology and motor outcomes (<xref ref-type="bibr" rid="bib36">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Kim et al., 2018</xref>). Our data demonstrate curli-dependent increases of inflammatory markers in both the intestine and brain, as well as acceleration of αSyn pathology, but do not determine which of these may be the primary driver of curli-mediated pathophysiology. Disentangling these complex relationships in future studies will define how pathologic signals from bacterial amyloids are transduced from the gut to the brain, via transneuronal spread of αSyn aggregates and/or an inflammatory cascade, and mechanisms of gut-to-brain signaling that contribute to motor impairment.</p><p>Synucleinopathy is linked to marked changes to the structure of the microbiome. Numerous studies have reported microbiome differences in persons with PD compared to unaffected individuals (<xref ref-type="bibr" rid="bib26">Hasegawa et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Keshavarzian et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Scheperjans et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Unger et al., 2016</xref>; <xref ref-type="bibr" rid="bib2">Bedarf et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Hill-Burns et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Hopfner et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Barichella et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Lin et al., 2018</xref>); however, examination of the gut microbiome during other synucleinopathies, such as MSA or LBD are still in their infancy (<xref ref-type="bibr" rid="bib16">Engen et al., 2017</xref>). Some reports have identified the family Enterobacteriaceae as enriched in PD compared to unaffected individuals (<xref ref-type="bibr" rid="bib71">Unger et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Barichella et al., 2019</xref>). In those studies which performed correlation analysis between disease severity and microbiome composition, enrichment of Enterobacteriaceae is observed to be positively associated with worsened motor symptoms (<xref ref-type="bibr" rid="bib62">Scheperjans et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Li et al., 2017</xref>). To our knowledge, no study to date has identified differential abundance of <italic>csgA</italic> or curli-encoding genes specifically in human incidences, and only a single study to date has utilized metagenomic sequencing of the gut microbiome during PD (<xref ref-type="bibr" rid="bib2">Bedarf et al., 2017</xref>). Despite recent advances defining microbiome changes in neurodegenerative diseases, a contributing role by gut bacteria to synucleinopathies in humans remains correlative (reviewed in <xref ref-type="bibr" rid="bib61">Sampson, 2019</xref>). In experimental models, however, transplant of fecal microbiomes from PD patients into ASO mice results in greater motor deficits than microbiomes from healthy controls (<xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>), suggesting functional consequences to changes in gut microbial composition.</p><p>Although our findings herein are limited to a single transgenic animal mouse model, and similar pathologies are observed in aged rats and nematodes (<xref ref-type="bibr" rid="bib8">Chen et al., 2016</xref>), it is possible that these observations are model specific. Non-amyloid contributions from diverse gut bacteria are also likely to occur and influence neurodegenerative outcomes. For instance, enrichment of the gut bacterium <italic>Proteus mirabilis</italic>, or intestinal administration of its purified LPS, impairs the dopaminergic system of mice and increases susceptibility to neurotoxins (<xref ref-type="bibr" rid="bib10">Choi et al., 2018</xref>). Infection with Gram-negative bacteria, including <italic>Citrobacter</italic> sp. (a taxonomic relative of <italic>E. coli</italic>), can trigger a pathological process leading to neurodegenerative immune responses in the brain and loss of midbrain dopamine production in a PD-relevant mouse model (<xref ref-type="bibr" rid="bib49">Matheoud et al., 2019</xref>). In addition, specific microbiome-derived metabolites promote microglia maturation (<xref ref-type="bibr" rid="bib17">Erny et al., 2015</xref>) and enhance αSyn-dependent pathology in germ-free mice (<xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>). Conversely, specific microbial metabolites (<xref ref-type="bibr" rid="bib4">Blacher et al., 2019</xref>) or fecal microbiome transplants (<xref ref-type="bibr" rid="bib66">Sun et al., 2018</xref>) may provide protection from neurodegenerative insults.</p><p>While CsgA is one example of bacterially-produced amyloid, microbial amyloid formation in general may influence physiological processes with outcomes relevant for neurodegenerative disease (<xref ref-type="bibr" rid="bib21">Friedland and Chapman, 2017</xref>). For example, the <italic>Pseudomonas</italic> sp. functional amyloid, FapC, may also accelerate αSyn aggregation in vitro (<xref ref-type="bibr" rid="bib12">Christensen et al., 2019</xref>), and bacterial chaperones of CsgA modulate αSyn amyloidogenesis (<xref ref-type="bibr" rid="bib18">Evans et al., 2015</xref>). More broadly, CsgA is observed to accelerate amyloid β aggregation in vitro (<xref ref-type="bibr" rid="bib25">Hartman et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Perov et al., 2019</xref>), as well as the disease-associated amyloids, islet amyloid polypeptide (IAPP) and semen enhancer of viral infection (SEVI) in vitro (<xref ref-type="bibr" rid="bib25">Hartman et al., 2013</xref>), and serum amyloid A in mice (<xref ref-type="bibr" rid="bib47">Lundmark et al., 2005</xref>). Emerging evidence in diverse animal models suggests that gut bacteria may modulate amyloid-driven diseases, not only in synucleinopathy as we and others describe, but Alzheimer’s disease (<xref ref-type="bibr" rid="bib24">Harach et al., 2017</xref>; <xref ref-type="bibr" rid="bib15">Dodiya et al., 2019</xref>) and amyotrophic lateral sclerosis (ALS) as well (<xref ref-type="bibr" rid="bib4">Blacher et al., 2019</xref>), providing justification for future human studies and revealing possible new targets for interventions that may prevent, slow, or halt amyloid formation and neurodegenerative disease.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Strain, strain background (<italic>Mus musculus</italic>)</td><td valign="top">Thy1- alpha-synuclein (Line 61), BDF1 background</td><td valign="top"><xref ref-type="bibr" rid="bib58">Rockenstein et al., 2002</xref></td><td valign="top">ASO (<bold><underline>a</underline></bold>lpha-<bold><underline>s</underline></bold>ynuclein <bold><underline>o</underline></bold>ver-expressing)</td><td valign="top">With permission, UCSD</td></tr><tr><td valign="top">Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="top">Str. K12, MC4100</td><td valign="top"><xref ref-type="bibr" rid="bib80">Zhou et al., 2013</xref></td><td valign="top">WT (wild-type)</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="top">Str. K12, MC4100:Δ<italic>csgBAC</italic></td><td valign="top"><xref ref-type="bibr" rid="bib80">Zhou et al., 2013</xref></td><td valign="top">Δ<italic>csgBAC</italic></td><td valign="top"/></tr><tr><td valign="top">Strain (<italic>Escherichia coli</italic>)</td><td valign="top">Str. K12, MC4100: CsgA:Q49A/N54A/Q139A/N144A</td><td valign="top"><xref ref-type="bibr" rid="bib77">Wang and Chapman, 2008</xref></td><td valign="top">SlowGo</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-alpha synuclein, mouse monoclonal</td><td valign="top">BD</td><td valign="top">Cat#: 610787</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-pS129 alpha-synuclein, rabbit monoclonal</td><td valign="top">AbCam</td><td valign="top">Cat#: Ab51253</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-tyrosine hydroxylase, mouse monoclonal</td><td valign="top">Millipore</td><td valign="top">Cat#: MAB318</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Iba1, rabbit</td><td valign="top">Wako</td><td valign="top">Cat#: 019–19741</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-aggregated alpha-synuclein, rabbit polyclonal</td><td valign="top">AbCam</td><td valign="top">Cat#: MJFR-14-6-4-2</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-mouse IgG-546, goat polyclonal</td><td valign="top">Life Technologies</td><td valign="top">Cat#: A-11003</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-rabbit IgG-546, goat polyclonal</td><td valign="top">Life Technologies</td><td valign="top">Cat#: A-11010</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-mouse IgG-488, goat polyclonal</td><td valign="top">Life Technologies</td><td valign="top">Cat#: A-11001</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-rabbit IgG-HRP, goat polyclonal</td><td valign="top">Cell Signaling</td><td valign="top">Cat#: 7074</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">CsgA (N’-QYGGNN-C’)</td><td valign="top">Bio-Synthesis, Inc; <xref ref-type="bibr" rid="bib68">Tükel et al., 2009</xref></td><td valign="top">CsgA</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">N122A (N’QYGGNA-C’)</td><td valign="top">Bio-Synthesis, Inc; <xref ref-type="bibr" rid="bib68">Tükel et al., 2009</xref></td><td valign="top">N122A</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">16S rRNA: <break/>5’-<named-content content-type="sequence">TCCTACGGGAGGCAGCAGT</named-content>-3’ and <break/>5’-<named-content content-type="sequence">GGACTACCAGGGTATCTAATCCTGTT</named-content>-3’</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>rrsA:</italic> <break/>5’-<named-content content-type="sequence">AGTGATAAACTGGAGGAGGTG</named-content>-3‘ and <break/>5’-<named-content content-type="sequence">GGACTACGACGCACTTTATGAG</named-content>-3’</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>csgA:</italic> <break/>5’-<named-content content-type="sequence">ATGACGGTTAAACAGTTCGG</named-content>-3’ and <break/>5’-<named-content content-type="sequence">AGGAGTTAGATGCAGTCTGG</named-content>-3’</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>gapdh</italic>: <break/>5’-<named-content content-type="sequence">CATGGCCTTCCGTGTTCCTA</named-content>-3’ and <break/>5’-<named-content content-type="sequence">CCTGCTTCACCACCTTCTTGAT</named-content>-3’</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>il6:</italic> <break/>5’-<named-content content-type="sequence">TAGTCCTTCCTACCCCAATTTCC</named-content>-3’ and <break/>5’-<named-content content-type="sequence">TTGGTCCTTAGCCACTCCTTC</named-content>-3’,</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>TH:</italic> <break/>5’-<named-content content-type="sequence">CCAAGGTTCATTGGACGGC</named-content>-3’ and <break/>5’-<named-content content-type="sequence">CTCTCCTCGAATACCACAGCC</named-content>-3’</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>tnfa</italic>; <break/>5’-<named-content content-type="sequence">CCCTCACACTCAGATCATCTTCT</named-content>-3’ and <break/>5’-<named-content content-type="sequence">GCTACGACAGTGGGCTACAG</named-content>-3’</td><td valign="top">IDT</td><td valign="top">qPCR primer</td><td valign="top">PrimerBank</td></tr></tbody></table></table-wrap><sec id="s3-1"><title>Animals</title><p>Male wild-type and Thy1-αSyn mice (Line 61, with permission from University of California, San Diego) were generated as described previously (<xref ref-type="bibr" rid="bib58">Rockenstein et al., 2002</xref>; <xref ref-type="bibr" rid="bib9">Chesselet et al., 2012</xref>; <xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>), through breeding female BDF1 background Thy1-αSyn mice to male BDF1 offspring generated via crossing female C57BL/6 with DBA/2 males (Charles River, Hollister, CA), and refreshing breeding pairs ~ 6 months. Germ-free (GF) Thy1-αSyn breeding pairs were generated via caesarian section and cross-fostered by GF Swiss-Webster dams. Conventionally colonized and mono-colonized animals were housed in autoclaved, ventilated, microisolator caging. GF animals were housed in open-top caging within flexible film isolators and maintained microbiologically sterile, confirmed via 16S rRNA PCR from fecal-derived DNA and culture of fecal pellets on Brucella blood agar or tryptic soy blood agar (Teknova, Hollister, CA) under anaerobic and aerobic conditions, respectively. Mono-colonized animals received ~10<sup>8</sup> cfu of the indicated bacterial strains in ~100 μL sodium bicarbonate buffer (5% w/v) at 5–6 weeks of age. Human microbiome colonized animals received ~100 μL 0.1 g/mL fecal extract from previously sampled healthy human donor (ENA Accession: PRJEB17694; Sample #: 10483.donor2.HC; MMA_008 [<xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>], California Institute of Technology’s Institutional Review Board #15–0568- exempt), at 5–6 weeks of age. For mice mono-colonized with <italic>E. coli</italic> containing plasmid vectors for CsgA and CsgA:SlowGo, drinking water was supplemented with 50 μg/mL kanamycin (Sigma Aldrich, St Louis, MO). Human microbiome colonized mice were associated with WT or Δ<italic>csgBAC</italic> mutant <italic>E. coli</italic> at time of microbiota transplant. For epigallocatechin gallate (EGCG) treatment, animals received filter-sterilized EGCG (Sigma Aldrich) at 200 μg/mL in drinking water ad libitum beginning at 5–6 weeks of age. All animals received autoclaved food (LabDiet Laboratory Autoclavable Diet 5010, St Louis, MO) and water ad libitum, were maintained on the same 12 hr light-dark cycle, and housed in the same room of the facility. All animal husbandry and experiments were approved by the California Institute of Technology’s Institutional Animal Care and Use Committee (IACUC), through protocol #1707.</p></sec><sec id="s3-2"><title>Motor function assessment</title><p>Motor function was assessed similarly to previous studies (<xref ref-type="bibr" rid="bib19">Fleming et al., 2004</xref>; <xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>), between hours 7 and 9 of the light phase, within a biosafety cabinet. Beam traversal and pole descent were performed first, followed by fecal output measurement. One day later, wirehang, adhesive removal and hindlimb scoring was performed. <italic>Beam traversal</italic>- A 1 m plexiglass beam consisting of four segments of 0.25 m in length (Stark’s Plastics, Forest Park, OH) was constructed with consecutively thinner widths of 3.5, 2.5, 1.5, and 0.5 cm, with 1 cm overhangs placed 1 cm below the surface of the beam and the narrowest end placed into home cage. Animals were trained for two consecutive days before the first testing. On the first day of training, animals received one trial with the home cage positioned close to the widest segment, where the animal was placed, and guided the animals forward along the narrowing beam. Animals received two more trials with limited or no assistance to encourage forward movement and stability on the beam. On the seccond day of training, animals were given three trials to traverse the beam, with little to no assistance. On the third day, animals were timed over three trials to traverse from the widest segment to the home cage. Time was measured from the placement of the animal’s forelimbs onto the second segment until a forelimb reached the home cage. Score was averaged over three trials. <italic>Pole descent</italic>- A 0.5 m long pole, 1 cm in diameter, wrapped with non-adhesive shelf liner to facilitate the animals grip, was placed into the home cage, with animals removed and placed into fresh housing. Animals received 2 days of training to descend from the top of the pole and into the home cage. On the first day, animals received three trials to descend the pole. First animals were placed head-down ~1/3 the distance above the base, the second trial from ~2/3 the height, and on the third trial animals were placed at the top of the pole, head-down. The second day of training, animals were tasked with descending, head-down, from the top of the pole, three times. On the day of testing, animals were placed head-down on the top of the pole and timed beginning when the experimenter released the animal and ended when one hind-limb was placed on the pole base. Score was averaged over three trials. <italic>Adhesive removal</italic>- ¼” round adhesive labels (Avery, Glendale, CA) were placed on the nasal bridge. Animals were placed into their home cage (with cage mates removed into separate cage) and timed to completely remove the sticker. Animals were recorded over two trials, and averaged. <italic>Hindlimb clasping reflex scoring</italic>- Animals were gently lifted by the mid-section of the tail and observed over ~5–10 s (<xref ref-type="bibr" rid="bib79">Zhang et al., 2014</xref>). Animals were assigned a score of 0, 1, 2, or 3. 0 was scored to animals that freely moved both their limbs and extended them outwards. A 1 was assigned to animals which clasped one hindlimb inward for the duration of the restraint or if both legs exhibited partial inward clasping. 2 was given if both legs clasped inward for the majority of the observation, but still exhibited some flexibility. A score of 3 was assigned if animals displayed complete rigidity of hindlimbs that immediately clasped inward and exhibited no signs of flexibility. For animals in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2G</xref>, animals were scored twice on 2 consecutive days and the score averaged, the remainder were scored once. <italic>Wirehang-</italic> Animals were placed in the center of a 30 cm by 30 cm screen with 1 cm wide mesh. The screen was inverted head-over-tail and placed on supports ~ 40 cm above an open cage with deep bedding. Animals were timed until they released their grip or remained for 60 s, and the score from two trials averaged. <italic>Fecal Output</italic>- Animals were removed from their home cages and placed into a 12 cm x 25 cm translucent cylinder. Fecal pellets were counted every 5 min, cumulative over 15 min. <italic>Principal component analysis</italic>- PCA was performed using ClustVis web tool, with default settings and reversed axis for display (<xref ref-type="bibr" rid="bib51">Metsalu and Vilo, 2015</xref>).</p></sec><sec id="s3-3"><title>Bacterial strains, manipulations, and characterizations</title><p> <italic>Escherichia coli</italic> K12 str. MC4100 and the previously characterized isogenic deletion mutant of the <italic>csgBAC</italic> operon were cultured aerobically in YESCA media at 37°C (<xref ref-type="bibr" rid="bib80">Zhou et al., 2013</xref>). Biofilm assays were performed via crystal violet staining of static culture at room temperature in YESCA as described previously (<xref ref-type="bibr" rid="bib80">Zhou et al., 2013</xref>). Congo red staining was performed on YESCA agar following 2–3 days growth at room temperature as described previously (<xref ref-type="bibr" rid="bib80">Zhou et al., 2013</xref>). Fecal bacterial DNA was isolated using QuickDNA Fecal/Soil Microbe Miniprep (Zymo Research, Irvine, CA). Fecal bacterial RNA was isolated using PowerMicrobiome RNA Isolation kit (MoBio, Carlsbad, CA) and cDNA generated via iScript cDNA Synthesis kit (BioRad, Hercules, CA). qPCR was performed with SybrGreen master mix (Applied Biosystems, Foster City, CA) on an AB7900ht instrument using the following primers: 16 s rRNA-5’-<named-content content-type="sequence">TCCTACGGGAGGCAGCAGT</named-content>-3’ and 5’-<named-content content-type="sequence">GGACTACCAGGGTATCTAATCCTGTT</named-content>-3’; <italic>rrsA</italic>-5’-<named-content content-type="sequence">AGTGATAAACTGGAGGAGGTG</named-content>- ‘and 5’-<named-content content-type="sequence">GGACTACGACGCACTTTATGAG</named-content>-3’; <italic>csgA</italic>- 5’-<named-content content-type="sequence">ATGACGGTTAAACAGTTCGG</named-content>-3’ and 5’-<named-content content-type="sequence">AGGAGTTAGATGCAGTCTGG</named-content>-3’. <italic>Bacteroides fragilis</italic> str. NTCT9343 was cultured anaerobically in brain-heart infusion (BHI) broth at 37°C, and colonized into GF animals via oral gavage of ~10<sup>8</sup> cfu in 100 μL sodium bicarbonate buffer (5% w/v) at 5–6 weeks of age. Segmented filamentous bacteria were colonized via bedding transfer and co-housing within a mono-associated gnotobiotic isolator. Colonization was confirmed by PCR for SFB 16 s RNA. For growth curves, <italic>E. coli</italic> was first grown aerobically at 37°C overnight in BHI broth, and subcultured at 1:400 in BHI containing indicated concentrations of EGCG, in a 200 μL volume in a 96-well plate. Plates were incubated at 37°C aerobically, with orbital shaking in a BioTek Cytation 5 plate reader, and the optical density at 600 nm measured every hour. Endotoxin content was measured following overnight growth at 37°C, aerobically in BHI using the Pierce LAL Chromogenic Endotoxin kit (ThermoFisher, Pittsburgh, PA) according to manufacturer’s instructions. LPS was stained from lysates derived from identically grown bacterial cultures following separation on a 4–20% SDS-PAGE gel with Pro-Q Emerald 300 LPS stain kit (ThermoFisher), according to manufacturer’s instructions.</p></sec><sec id="s3-4"><title>α-Synuclein aggregation assays</title><p> <italic>Thioflavin T (ThT) assays-</italic>Freshly purified CsgA (both wild-type and ‘SlowGo’) and αSyn were diluted in 50 mM KPi (pH 7.3) to the molar concentrations indicated in each experiment. Samples were incubated in 96-well, black, flat bottom plates at 37°C with 20 μM ThT and 100 mM NaCl under continuous shaking conditions, along with a 1 mm glass bead for homogenous mixing. The ThT fluorescence intensity was recorded in 30 min interval using a Tecan plate reader (excitation: 438 nm; emission: 495 nm; cut-off: 475 nm). <italic>TauK18 aggregation assay-</italic> 50 µM of TauK18 fragment with heparin (TauK18:Heparin 4:1) was incubated with or without CsgA (2 µM) in 14 mM MES buffer pH 6.8 at 37°C with continuous shaking in 96-well, black, flat bottom plates. 2 mm beads and 20 µM ThT was added to all the wells. The ThT fluorescence was monitored with previously mentioned parameters after 30 min in FLUOstar omega plate reader (BMG Labtech). <italic>Transmission electron microscopy-</italic> Aliquots of CsgA and αSyn reactions were taken at indicated timepoints. Five microliters of sample was applied on glow-discharged carbon-coated grids, incubated for 1 min and washed with MilliQ water before staining with 1% uranyl acetate. Samples were imaged on Jeol electron microscope (JEOL-1400 plus). <italic>Circular dichroism spectroscopy-</italic> αSyn alone or with CsgA (in 20 mM KPi pH 7.3) were analyzed using a Jasco J-810 spectropolarimeter from 190 nm to 250 nm at 25°C immediately after purification and at indicated timepoints.</p></sec><sec id="s3-5"><title>Synuclein pathology and inflammatory responses</title><p> <italic>CD11b enrichment-</italic> Animals were sedated with pentobarbital and perfused; whole brains were homogenized in PBS via passage through a 100 μm mesh filter, myelin debris were removed using magnetic separation with Myelin Removal Beads (Miltenyi Biotec, San Diego, CA), and subsequently CD11b positive enrichment performed similarly, via Microglia Microbeads (Miltenyi Biotec), according to manufacturer’s instructions. Cells were immediately lysed in Trizol and RNA extracted with the DirectZol RNA extraction (Zymo Research). cDNA and qPCR performed as described above with primers- <italic>gapdh</italic>: 5’-<named-content content-type="sequence">CATGGCCTTCCGTGTTCCTA</named-content>-3’ and 5’-<named-content content-type="sequence">CCTGCTTCACCACCTTCTTGAT</named-content>-3’; <italic>il6:</italic> 5’-<named-content content-type="sequence">TAGTCCTTCCTACCCCAATTTCC</named-content>-3’ and 5’-<named-content content-type="sequence">TTGGTCCTTAGCCACTCCTTC</named-content>-3’, <italic>tyrosine hydroxylase:</italic> 5’-<named-content content-type="sequence">CCAAGGTTCATTGGACGGC</named-content>-3’ and 5’-<named-content content-type="sequence">CTCTCCTCGAATACCACAGCC</named-content>-3’; and <italic>tnfa</italic>; 5’-<named-content content-type="sequence">CCCTCACACTCAGATCATCTTCT</named-content>-3’ and 5’-<named-content content-type="sequence">gctacgacagtgggctacag</named-content>-3’. <italic>Synuclein imaging</italic>- Perfused whole brains were dissected and fixed with 4% (w/v) paraformaldehyde. 50 μm sections were generated via vibratome. For proteinase-K resistant staining, free-floating sections were treated briefly with 5 μg/mL proteinase K (NEB, Ipswich, MA) and stained with anti-alpha synuclein (1:1000 mouse; #610787 BD, Franklin Lakes, NJ), pS129-synuclein staining utilized anti-pS129syn (1:1000 rabbit; #ab51253 AbCam, Cambridge, UK) and anti-tyrosine hydroxylase (1:1000 mouse; MAB318, Millipore, Burlington, MA). Sections were stained with secondary anti-mouse IgG-AF488 (1:1000, Life Technologies, Carlsbad, CA), anti-rabbit IgG-546 (1:1000, Life Technologies) and Neurotrace (Life Technologies), mounted with ProFade Diamond DAPI (Life Technologies) and imaged with a 20x objective on a Zeiss LSM800 confocal microscope. Sections corresponding to ~1500 μm from midline were counted manually for TH<sup>+</sup> cell bodies and pS129syn puncta in ImageJ software. <italic>Microglia reconstructions</italic>- Microglia were imaged and analyzed as previously described (<xref ref-type="bibr" rid="bib17">Erny et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Sampson et al., 2016</xref>). Thin sections prepared as above were stained with anti-Iba1 (1:1000 rabbit, Wako, Richmond, VA) and anti-rabbit IgG-AF546 (1:1000, Life Technologies). Z-stacks were imaged at 1 μm steps and analyzed using Imaris software. <italic>ELISAs</italic>- For TNFα and IL6 (eBioscience, San Diego, CA), αSyn (ThermoFisher), and dopamine (Eagle Biosciences, Nashua, NH) tissue homogenates were prepared in RIPA buffer containing protease inhibitor (ThermoFisher), and ELISA performed according to manufacturer’s instructions with 100 μg of tissue. Multiplexed intestine (100 μg) and serum cytokine levels were measured on a Bio-Plex 200 using the Bio-Plex Mouse Cytokine 23-plex Assay (Biorad) according to manufacturer’s instructions. <italic>Dot blot</italic>- Tissue homogenates were spotted onto 0.45 μm nitrocellulose membranes, in 1 μg/μL aliquots. Membranes were blocked with 5% dry skim milk in Tris-buffered saline and stained with anti-aggregated alpha-synuclein antibody (1:1000, MJFR-14-6-4-2, rabbit, AbCam) and anti-rabbit IgG-HRP (1:1000, Cell Signaling Technology, Danvers, MA), and detected with Clarity chemiluminescence substrate (BioRad) on a BioRad GelDoc XR and densitometry performed.</p></sec><sec id="s3-6"><title>Intestinal injections</title><p>Synthetic hexapeptides of CsgA (Nterm-QYGGNN-Cterm) and the non-amyloidogenic mutant N122A (Nterm-QYGGNA-Cterm) were purchased from Bio-Synthesis Inc (Lewisville, TX). Mice were anesthetized with isoflurane (1–4% vol/vol) and kept on a self-regulating heating pad throughout the procedure. A 10 µl Hamilton syringe fitted with a 36-gauge beveled needle was loaded with 30 µg of either hexapeptide in saline (9 µl total). Each animal was injected in three locations (both sides of pyloric antrum and duodenum [0.5 cm past the pyloric sphincter]; 3 µl each location) by inserting the needle tip bevel facing up into the intestine wall at a 15° angle. After injection, the abdominal muscle/peritoneal layer and skin were sutured separately, then mice returned to home cages. Mice were injected subcutaneously with buprenorphine SR (1 mg/kg) and monitored for 3 days for normal food and water consumption.</p></sec><sec id="s3-7"><title>Statistics and data availability</title><p>Data were analyzed in GraphPad Prism, with the analysis indicated in each figure legend. Statistical output and numerical source data presented within the manuscript are available within the supplementary information included with this manuscript.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Drs. E Hsiao, M Sampson, S Campbell, D Yamashita, D Donabedian, and members of the SKM laboratory for helpful critiques and review of this manuscript. We are grateful to J Paramo, S Estrada, K Ly and the Caltech OLAR staff for animal care husbandry, and Y Garcia-Flores (Caltech) for technical support. Electron micrographs of amyloids were generated at the Microscopy and Imaging Analysis Laboratory Core at the University of Michigan. Fluorescent imaging and image analysis were performed in the Caltech Biological Imaging Facility, with the support of the Caltech Beckman Institute and the Arnold and Mabel Beckman Foundation. TRS was a Larry L Hillblom Foundation postdoctoral fellow. This project was supported by funds from the Heritage Medical Research Institute to VG and SKM; the Knut and Alice Wallenberg Foundation and Swedish Research Council to PW-S; the National Institutes of Health grants AG054101 (CC), GM118651 (MRC) and NS085910 (SKM); Axial Biotherapeutics to SKM; and the Department of Defense grant PD160030 to SKM.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>has intellectual property pending in relationship to the content of this manuscript, US Patent App. 15/893,456 and 16/302,321.</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>a member of the Scientific Advisory Board of Axial Biotherapeutics.</p></fn><fn fn-type="COI-statement" id="conf4"><p>has financial interest in Axial Biotherapeutics. Has intellectual property pending in relationship to the content of this manuscript, US Patent App. 15/893,456 and 16/302,321.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Visualization</p></fn><fn fn-type="con" id="con2"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con3"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con4"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con5"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation, Visualization</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Supervision</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Supervision</p></fn><fn fn-type="con" id="con14"><p>Supervision</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal husbandry and experiments were approved by the California Institute of Technology's Institutional Animal Care and Use Committee (IACUC) under protocol #1707.</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-53111-transrepform-v1.pdf"/></supplementary-material></sec><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files and statistical output for all figures have been provided.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barichella</surname> <given-names>M</given-names></name><name><surname>Severgnini</surname> <given-names>M</given-names></name><name><surname>Cilia</surname> <given-names>R</given-names></name><name><surname>Cassani</surname> <given-names>E</given-names></name><name><surname>Bolliri</surname> <given-names>C</given-names></name><name><surname>Caronni</surname> <given-names>S</given-names></name><name><surname>Ferri</surname> <given-names>V</given-names></name><name><surname>Cancello</surname> <given-names>R</given-names></name><name><surname>Ceccarani</surname> <given-names>C</given-names></name><name><surname>Faierman</surname> <given-names>S</given-names></name><name><surname>Pinelli</surname> <given-names>G</given-names></name><name><surname>Bellis</surname> <given-names>G</given-names></name><name><surname>Zecca</surname> <given-names>L</given-names></name><name><surname>Cereda</surname> <given-names>E</given-names></name><name><surname>Consolandi</surname> <given-names>C</given-names></name><name><surname>Pezzoli</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Unraveling gut Microbiota in Parkinson's disease and atypical parkinsonism</article-title><source>Movement Disorders</source><volume>34</volume><fpage>396</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/mds.27581</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedarf</surname> <given-names>JR</given-names></name><name><surname>Hildebrand</surname> <given-names>F</given-names></name><name><surname>Coelho</surname> <given-names>LP</given-names></name><name><surname>Sunagawa</surname> <given-names>S</given-names></name><name><surname>Bahram</surname> <given-names>M</given-names></name><name><surname>Goeser</surname> <given-names>F</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Wüllner</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve parkinson's disease patients</article-title><source>Genome Medicine</source><volume>9</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-017-0428-y</pub-id><pub-id pub-id-type="pmid">28449715</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieschke</surname> <given-names>J</given-names></name><name><surname>Russ</surname> <given-names>J</given-names></name><name><surname>Friedrich</surname> <given-names>RP</given-names></name><name><surname>Ehrnhoefer</surname> <given-names>DE</given-names></name><name><surname>Wobst</surname> <given-names>H</given-names></name><name><surname>Neugebauer</surname> <given-names>K</given-names></name><name><surname>Wanker</surname> <given-names>EE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity</article-title><source>PNAS</source><volume>107</volume><fpage>7710</fpage><lpage>7715</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910723107</pub-id><pub-id pub-id-type="pmid">20385841</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blacher</surname> <given-names>E</given-names></name><name><surname>Bashiardes</surname> <given-names>S</given-names></name><name><surname>Shapiro</surname> <given-names>H</given-names></name><name><surname>Rothschild</surname> <given-names>D</given-names></name><name><surname>Mor</surname> <given-names>U</given-names></name><name><surname>Dori-Bachash</surname> <given-names>M</given-names></name><name><surname>Kleimeyer</surname> <given-names>C</given-names></name><name><surname>Moresi</surname> <given-names>C</given-names></name><name><surname>Harnik</surname> <given-names>Y</given-names></name><name><surname>Zur</surname> <given-names>M</given-names></name><name><surname>Zabari</surname> <given-names>M</given-names></name><name><surname>Brik</surname> <given-names>RB-Z</given-names></name><name><surname>Kviatcovsky</surname> <given-names>D</given-names></name><name><surname>Zmora</surname> <given-names>N</given-names></name><name><surname>Cohen</surname> <given-names>Y</given-names></name><name><surname>Bar</surname> <given-names>N</given-names></name><name><surname>Levi</surname> <given-names>I</given-names></name><name><surname>Amar</surname> <given-names>N</given-names></name><name><surname>Mehlman</surname> <given-names>T</given-names></name><name><surname>Brandis</surname> <given-names>A</given-names></name><name><surname>Biton</surname> <given-names>I</given-names></name><name><surname>Kuperman</surname> <given-names>Y</given-names></name><name><surname>Tsoory</surname> <given-names>M</given-names></name><name><surname>Alfahel</surname> <given-names>L</given-names></name><name><surname>Harmelin</surname> <given-names>A</given-names></name><name><surname>Schwartz</surname> <given-names>M</given-names></name><name><surname>Israelson</surname> <given-names>A</given-names></name><name><surname>Arike</surname> <given-names>L</given-names></name><name><surname>Johansson</surname> <given-names>MEV</given-names></name><name><surname>Hansson</surname> <given-names>GC</given-names></name><name><surname>Gotkine</surname> <given-names>M</given-names></name><name><surname>Segal</surname> <given-names>E</given-names></name><name><surname>Elinav</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Potential roles of gut microbiome and metabolites in modulating ALS in mice</article-title><source>Nature</source><volume>572</volume><fpage>474</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1443-5</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname> <given-names>H</given-names></name><name><surname>Rüb</surname> <given-names>U</given-names></name><name><surname>Gai</surname> <given-names>WP</given-names></name><name><surname>Del Tredici</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen</article-title><source>Journal of Neural Transmission</source><volume>110</volume><fpage>517</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1007/s00702-002-0808-2</pub-id><pub-id pub-id-type="pmid">12721813</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brettschneider</surname> <given-names>J</given-names></name><name><surname>Del Tredici</surname> <given-names>K</given-names></name><name><surname>Lee</surname> <given-names>VM</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spreading of pathology in neurodegenerative diseases: a focus on human studies</article-title><source>Nature Reviews Neuroscience</source><volume>16</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nrn3887</pub-id><pub-id pub-id-type="pmid">25588378</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>Z-Y</given-names></name><name><surname>Li</surname> <given-names>X-M</given-names></name><name><surname>Liang</surname> <given-names>J-P</given-names></name><name><surname>Xiang</surname> <given-names>L-P</given-names></name><name><surname>Wang</surname> <given-names>K-R</given-names></name><name><surname>Shi</surname> <given-names>Y-L</given-names></name><name><surname>Yang</surname> <given-names>R</given-names></name><name><surname>Shi</surname> <given-names>M</given-names></name><name><surname>Ye</surname> <given-names>J-H</given-names></name><name><surname>Lu</surname> <given-names>J-L</given-names></name><name><surname>Zheng</surname> <given-names>X-Q</given-names></name><name><surname>Liang</surname> <given-names>Y-R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bioavailability of tea catechins and its improvement</article-title><source>Molecules</source><volume>23</volume><elocation-id>2346</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23092346</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>SG</given-names></name><name><surname>Stribinskis</surname> <given-names>V</given-names></name><name><surname>Rane</surname> <given-names>MJ</given-names></name><name><surname>Demuth</surname> <given-names>DR</given-names></name><name><surname>Gozal</surname> <given-names>E</given-names></name><name><surname>Roberts</surname> <given-names>AM</given-names></name><name><surname>Jagadapillai</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Choe</surname> <given-names>K</given-names></name><name><surname>Shivakumar</surname> <given-names>B</given-names></name><name><surname>Son</surname> <given-names>F</given-names></name><name><surname>Jin</surname> <given-names>S</given-names></name><name><surname>Kerber</surname> <given-names>R</given-names></name><name><surname>Adame</surname> <given-names>A</given-names></name><name><surname>Masliah</surname> <given-names>E</given-names></name><name><surname>Friedland</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Exposure to the functional bacterial amyloid protein curli enhances Alpha-Synuclein aggregation in aged Fischer 344 rats and <italic>Caenorhabditis elegans</italic></article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>34477</elocation-id><pub-id pub-id-type="doi">10.1038/srep34477</pub-id><pub-id pub-id-type="pmid">27708338</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesselet</surname> <given-names>MF</given-names></name><name><surname>Richter</surname> <given-names>F</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name><name><surname>Magen</surname> <given-names>I</given-names></name><name><surname>Watson</surname> <given-names>MB</given-names></name><name><surname>Subramaniam</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A progressive mouse model of Parkinson's disease: the Thy1-aSyn (&quot;Line 61&quot;) mice</article-title><source>Neurotherapeutics</source><volume>9</volume><fpage>297</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s13311-012-0104-2</pub-id><pub-id pub-id-type="pmid">22350713</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>JG</given-names></name><name><surname>Kim</surname> <given-names>N</given-names></name><name><surname>Ju</surname> <given-names>IG</given-names></name><name><surname>Eo</surname> <given-names>H</given-names></name><name><surname>Lim</surname> <given-names>SM</given-names></name><name><surname>Jang</surname> <given-names>SE</given-names></name><name><surname>Kim</surname> <given-names>DH</given-names></name><name><surname>Oh</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>1275</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-19646-x</pub-id><pub-id pub-id-type="pmid">29352191</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chorell</surname> <given-names>E</given-names></name><name><surname>Andersson</surname> <given-names>E</given-names></name><name><surname>Evans</surname> <given-names>ML</given-names></name><name><surname>Jain</surname> <given-names>N</given-names></name><name><surname>Götheson</surname> <given-names>A</given-names></name><name><surname>Åden</surname> <given-names>J</given-names></name><name><surname>Chapman</surname> <given-names>MR</given-names></name><name><surname>Almqvist</surname> <given-names>F</given-names></name><name><surname>Wittung-Stafshede</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bacterial chaperones CsgE and CsgC differentially modulate human α-Synuclein amyloid formation via transient contacts</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0140194</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0140194</pub-id><pub-id pub-id-type="pmid">26465894</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname> <given-names>LFB</given-names></name><name><surname>Jensen</surname> <given-names>KF</given-names></name><name><surname>Nielsen</surname> <given-names>J</given-names></name><name><surname>Vad</surname> <given-names>BS</given-names></name><name><surname>Christiansen</surname> <given-names>G</given-names></name><name><surname>Otzen</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reducing the amyloidogenicity of functional amyloid protein FapC increases its ability to inhibit α-Synuclein fibrillation</article-title><source>ACS Omega</source><volume>4</volume><fpage>4029</fpage><lpage>4039</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b03590</pub-id><pub-id pub-id-type="pmid">31459612</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clinton</surname> <given-names>LK</given-names></name><name><surname>Blurton-Jones</surname> <given-names>M</given-names></name><name><surname>Myczek</surname> <given-names>K</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name><name><surname>LaFerla</surname> <given-names>FM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Synergistic interactions between A , Tau, and -Synuclein: Acceleration of Neuropathology and Cognitive Decline</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>7281</fpage><lpage>7289</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0490-10.2010</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colosimo</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nonmotor presentations of multiple system atrophy</article-title><source>Nature Reviews Neurology</source><volume>7</volume><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2011.5</pub-id><pub-id pub-id-type="pmid">21343894</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodiya</surname> <given-names>HB</given-names></name><name><surname>Kuntz</surname> <given-names>T</given-names></name><name><surname>Shaik</surname> <given-names>SM</given-names></name><name><surname>Baufeld</surname> <given-names>C</given-names></name><name><surname>Leibowitz</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Gottel</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Butovsky</surname> <given-names>O</given-names></name><name><surname>Gilbert</surname> <given-names>JA</given-names></name><name><surname>Sisodia</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sex-specific effects of microbiome perturbations on cerebral aβ amyloidosis and microglia phenotypes</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>1542</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1084/jem.20182386</pub-id><pub-id pub-id-type="pmid">31097468</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engen</surname> <given-names>PA</given-names></name><name><surname>Dodiya</surname> <given-names>HB</given-names></name><name><surname>Naqib</surname> <given-names>A</given-names></name><name><surname>Forsyth</surname> <given-names>CB</given-names></name><name><surname>Green</surname> <given-names>SJ</given-names></name><name><surname>Voigt</surname> <given-names>RM</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name><name><surname>Mutlu</surname> <given-names>EA</given-names></name><name><surname>Shannon</surname> <given-names>KM</given-names></name><name><surname>Keshavarzian</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The potential role of Gut-Derived inflammation in multiple system atrophy</article-title><source>Journal of Parkinson's Disease</source><volume>7</volume><fpage>331</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.3233/JPD-160991</pub-id><pub-id pub-id-type="pmid">28234259</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erny</surname> <given-names>D</given-names></name><name><surname>Hrabě de Angelis</surname> <given-names>AL</given-names></name><name><surname>Jaitin</surname> <given-names>D</given-names></name><name><surname>Wieghofer</surname> <given-names>P</given-names></name><name><surname>Staszewski</surname> <given-names>O</given-names></name><name><surname>David</surname> <given-names>E</given-names></name><name><surname>Keren-Shaul</surname> <given-names>H</given-names></name><name><surname>Mahlakoiv</surname> <given-names>T</given-names></name><name><surname>Jakobshagen</surname> <given-names>K</given-names></name><name><surname>Buch</surname> <given-names>T</given-names></name><name><surname>Schwierzeck</surname> <given-names>V</given-names></name><name><surname>Utermöhlen</surname> <given-names>O</given-names></name><name><surname>Chun</surname> <given-names>E</given-names></name><name><surname>Garrett</surname> <given-names>WS</given-names></name><name><surname>McCoy</surname> <given-names>KD</given-names></name><name><surname>Diefenbach</surname> <given-names>A</given-names></name><name><surname>Staeheli</surname> <given-names>P</given-names></name><name><surname>Stecher</surname> <given-names>B</given-names></name><name><surname>Amit</surname> <given-names>I</given-names></name><name><surname>Prinz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Host Microbiota constantly control maturation and function of microglia in the CNS</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>965</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nn.4030</pub-id><pub-id pub-id-type="pmid">26030851</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>ML</given-names></name><name><surname>Chorell</surname> <given-names>E</given-names></name><name><surname>Taylor</surname> <given-names>JD</given-names></name><name><surname>Åden</surname> <given-names>J</given-names></name><name><surname>Götheson</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Koch</surname> <given-names>M</given-names></name><name><surname>Sefer</surname> <given-names>L</given-names></name><name><surname>Matthews</surname> <given-names>SJ</given-names></name><name><surname>Wittung-Stafshede</surname> <given-names>P</given-names></name><name><surname>Almqvist</surname> <given-names>F</given-names></name><name><surname>Chapman</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The bacterial curli system possesses a potent and selective inhibitor of amyloid formation</article-title><source>Molecular Cell</source><volume>57</volume><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.12.025</pub-id><pub-id pub-id-type="pmid">25620560</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname> <given-names>SM</given-names></name><name><surname>Salcedo</surname> <given-names>J</given-names></name><name><surname>Fernagut</surname> <given-names>PO</given-names></name><name><surname>Rockenstein</surname> <given-names>E</given-names></name><name><surname>Masliah</surname> <given-names>E</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name><name><surname>Chesselet</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein</article-title><source>Journal of Neuroscience</source><volume>24</volume><fpage>9434</fpage><lpage>9440</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3080-04.2004</pub-id><pub-id pub-id-type="pmid">15496679</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsyth</surname> <given-names>CB</given-names></name><name><surname>Shannon</surname> <given-names>KM</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name><name><surname>Voigt</surname> <given-names>RM</given-names></name><name><surname>Shaikh</surname> <given-names>M</given-names></name><name><surname>Jaglin</surname> <given-names>JA</given-names></name><name><surname>Estes</surname> <given-names>JD</given-names></name><name><surname>Dodiya</surname> <given-names>HB</given-names></name><name><surname>Keshavarzian</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e28032</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0028032</pub-id><pub-id pub-id-type="pmid">22145021</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedland</surname> <given-names>RP</given-names></name><name><surname>Chapman</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of microbial amyloid in neurodegeneration</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006654</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006654</pub-id><pub-id pub-id-type="pmid">29267402</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname> <given-names>TC</given-names></name><name><surname>Olson</surname> <given-names>CA</given-names></name><name><surname>Hsiao</surname> <given-names>EY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interactions between the Microbiota, immune and nervous systems in health and disease</article-title><source>Nature Neuroscience</source><volume>20</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/nn.4476</pub-id><pub-id pub-id-type="pmid">28092661</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname> <given-names>PM</given-names></name><name><surname>Rapsinski</surname> <given-names>GJ</given-names></name><name><surname>Wilson</surname> <given-names>RP</given-names></name><name><surname>Oppong</surname> <given-names>GO</given-names></name><name><surname>Sriram</surname> <given-names>U</given-names></name><name><surname>Goulian</surname> <given-names>M</given-names></name><name><surname>Buttaro</surname> <given-names>B</given-names></name><name><surname>Caricchio</surname> <given-names>R</given-names></name><name><surname>Gallucci</surname> <given-names>S</given-names></name><name><surname>Tükel</surname> <given-names>Ç</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity</article-title><source>Immunity</source><volume>42</volume><fpage>1171</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.06.002</pub-id><pub-id pub-id-type="pmid">26084027</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harach</surname> <given-names>T</given-names></name><name><surname>Marungruang</surname> <given-names>N</given-names></name><name><surname>Duthilleul</surname> <given-names>N</given-names></name><name><surname>Cheatham</surname> <given-names>V</given-names></name><name><surname>Mc Coy</surname> <given-names>KD</given-names></name><name><surname>Frisoni</surname> <given-names>G</given-names></name><name><surname>Neher</surname> <given-names>JJ</given-names></name><name><surname>Fåk</surname> <given-names>F</given-names></name><name><surname>Jucker</surname> <given-names>M</given-names></name><name><surname>Lasser</surname> <given-names>T</given-names></name><name><surname>Bolmont</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Reduction of abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut Microbiota</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>41802</elocation-id><pub-id pub-id-type="doi">10.1038/srep41802</pub-id><pub-id pub-id-type="pmid">28176819</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname> <given-names>K</given-names></name><name><surname>Brender</surname> <given-names>JR</given-names></name><name><surname>Monde</surname> <given-names>K</given-names></name><name><surname>Ono</surname> <given-names>A</given-names></name><name><surname>Evans</surname> <given-names>ML</given-names></name><name><surname>Popovych</surname> <given-names>N</given-names></name><name><surname>Chapman</surname> <given-names>MR</given-names></name><name><surname>Ramamoorthy</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bacterial curli protein promotes the conversion of PAP <sub>248-286</sub> into the amyloid SEVI: cross-seeding of dissimilar amyloid sequences</article-title><source>PeerJ</source><volume>1</volume><elocation-id>e5</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.5</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname> <given-names>S</given-names></name><name><surname>Goto</surname> <given-names>S</given-names></name><name><surname>Tsuji</surname> <given-names>H</given-names></name><name><surname>Okuno</surname> <given-names>T</given-names></name><name><surname>Asahara</surname> <given-names>T</given-names></name><name><surname>Nomoto</surname> <given-names>K</given-names></name><name><surname>Shibata</surname> <given-names>A</given-names></name><name><surname>Fujisawa</surname> <given-names>Y</given-names></name><name><surname>Minato</surname> <given-names>T</given-names></name><name><surname>Okamoto</surname> <given-names>A</given-names></name><name><surname>Ohno</surname> <given-names>K</given-names></name><name><surname>Hirayama</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intestinal dysbiosis and lowered serum Lipopolysaccharide-Binding protein in Parkinson’s Disease</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0142164</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0142164</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill-Burns</surname> <given-names>EM</given-names></name><name><surname>Debelius</surname> <given-names>JW</given-names></name><name><surname>Morton</surname> <given-names>JT</given-names></name><name><surname>Wissemann</surname> <given-names>WT</given-names></name><name><surname>Lewis</surname> <given-names>MR</given-names></name><name><surname>Wallen</surname> <given-names>ZD</given-names></name><name><surname>Peddada</surname> <given-names>SD</given-names></name><name><surname>Factor</surname> <given-names>SA</given-names></name><name><surname>Molho</surname> <given-names>E</given-names></name><name><surname>Zabetian</surname> <given-names>CP</given-names></name><name><surname>Knight</surname> <given-names>R</given-names></name><name><surname>Payami</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome</article-title><source>Movement Disorders</source><volume>32</volume><fpage>739</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1002/mds.26942</pub-id><pub-id pub-id-type="pmid">28195358</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmqvist</surname> <given-names>S</given-names></name><name><surname>Chutna</surname> <given-names>O</given-names></name><name><surname>Bousset</surname> <given-names>L</given-names></name><name><surname>Aldrin-Kirk</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Björklund</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>ZY</given-names></name><name><surname>Roybon</surname> <given-names>L</given-names></name><name><surname>Melki</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Direct evidence of parkinson pathology spread from the gastrointestinal tract to the brain in rats</article-title><source>Acta Neuropathologica</source><volume>128</volume><fpage>805</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s00401-014-1343-6</pub-id><pub-id pub-id-type="pmid">25296989</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopfner</surname> <given-names>F</given-names></name><name><surname>Künstner</surname> <given-names>A</given-names></name><name><surname>Müller</surname> <given-names>SH</given-names></name><name><surname>Künzel</surname> <given-names>S</given-names></name><name><surname>Zeuner</surname> <given-names>KE</given-names></name><name><surname>Margraf</surname> <given-names>NG</given-names></name><name><surname>Deuschl</surname> <given-names>G</given-names></name><name><surname>Baines</surname> <given-names>JF</given-names></name><name><surname>Kuhlenbäumer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gut Microbiota in parkinson disease in a northern german cohort</article-title><source>Brain Research</source><volume>1667</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2017.04.019</pub-id><pub-id pub-id-type="pmid">28506555</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname> <given-names>KY</given-names></name><name><surname>Fernandez-Hernandez</surname> <given-names>H</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Schaffner</surname> <given-names>A</given-names></name><name><surname>Pankratz</surname> <given-names>N</given-names></name><name><surname>Hsu</surname> <given-names>N-Y</given-names></name><name><surname>Chuang</surname> <given-names>L-S</given-names></name><name><surname>Carmi</surname> <given-names>S</given-names></name><name><surname>Villaverde</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Rivas</surname> <given-names>M</given-names></name><name><surname>Levine</surname> <given-names>AP</given-names></name><name><surname>Bao</surname> <given-names>X</given-names></name><name><surname>Labrias</surname> <given-names>PR</given-names></name><name><surname>Haritunians</surname> <given-names>T</given-names></name><name><surname>Ruane</surname> <given-names>D</given-names></name><name><surname>Gettler</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Schiff</surname> <given-names>ER</given-names></name><name><surname>Pontikos</surname> <given-names>N</given-names></name><name><surname>Barzilai</surname> <given-names>N</given-names></name><name><surname>Brant</surname> <given-names>SR</given-names></name><name><surname>Bressman</surname> <given-names>S</given-names></name><name><surname>Cheifetz</surname> <given-names>AS</given-names></name><name><surname>Clark</surname> <given-names>LN</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Desnick</surname> <given-names>RJ</given-names></name><name><surname>Duerr</surname> <given-names>RH</given-names></name><name><surname>Katz</surname> <given-names>S</given-names></name><name><surname>Lencz</surname> <given-names>T</given-names></name><name><surname>Myers</surname> <given-names>RH</given-names></name><name><surname>Ostrer</surname> <given-names>H</given-names></name><name><surname>Ozelius</surname> <given-names>L</given-names></name><name><surname>Payami</surname> <given-names>H</given-names></name><name><surname>Peter</surname> <given-names>Y</given-names></name><name><surname>Rioux</surname> <given-names>JD</given-names></name><name><surname>Segal</surname> <given-names>AW</given-names></name><name><surname>Scott</surname> <given-names>WK</given-names></name><name><surname>Silverberg</surname> <given-names>MS</given-names></name><name><surname>Vance</surname> <given-names>JM</given-names></name><name><surname>Ubarretxena-Belandia</surname> <given-names>I</given-names></name><name><surname>Foroud</surname> <given-names>T</given-names></name><name><surname>Atzmon</surname> <given-names>G</given-names></name><name><surname>Pe’er</surname> <given-names>I</given-names></name><name><surname>Ioannou</surname> <given-names>Y</given-names></name><name><surname>McGovern</surname> <given-names>DPB</given-names></name><name><surname>Yue</surname> <given-names>Z</given-names></name><name><surname>Schadt</surname> <given-names>EE</given-names></name><name><surname>Cho</surname> <given-names>JH</given-names></name><name><surname>Peter</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Functional variants in the <italic>LRRK2</italic> gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaai7795</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aai7795</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>ME</given-names></name><name><surname>Stecher</surname> <given-names>B</given-names></name><name><surname>Labrie</surname> <given-names>V</given-names></name><name><surname>Brundin</surname> <given-names>L</given-names></name><name><surname>Brundin</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Triggers, facilitators, and aggravators: redefining Parkinson’s Disease Pathogenesis</article-title><source>Trends in Neurosciences</source><volume>42</volume><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2018.09.007</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jucker</surname> <given-names>M</given-names></name><name><surname>Walker</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Self-propagation of pathogenic protein aggregates in neurodegenerative diseases</article-title><source>Nature</source><volume>501</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nature12481</pub-id><pub-id pub-id-type="pmid">24005412</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katorcha</surname> <given-names>E</given-names></name><name><surname>Makarava</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>YJ</given-names></name><name><surname>Lindberg</surname> <given-names>I</given-names></name><name><surname>Monteiro</surname> <given-names>MJ</given-names></name><name><surname>Kovacs</surname> <given-names>GG</given-names></name><name><surname>Baskakov</surname> <given-names>IV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006563</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006563</pub-id><pub-id pub-id-type="pmid">28797122</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshavarzian</surname> <given-names>A</given-names></name><name><surname>Green</surname> <given-names>SJ</given-names></name><name><surname>Engen</surname> <given-names>PA</given-names></name><name><surname>Voigt</surname> <given-names>RM</given-names></name><name><surname>Naqib</surname> <given-names>A</given-names></name><name><surname>Forsyth</surname> <given-names>CB</given-names></name><name><surname>Mutlu</surname> <given-names>E</given-names></name><name><surname>Shannon</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Colonic bacterial composition in Parkinson's disease</article-title><source>Movement Disorders</source><volume>30</volume><fpage>1351</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1002/mds.26307</pub-id><pub-id pub-id-type="pmid">26179554</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killinger</surname> <given-names>BA</given-names></name><name><surname>Madaj</surname> <given-names>Z</given-names></name><name><surname>Sikora</surname> <given-names>JW</given-names></name><name><surname>Rey</surname> <given-names>N</given-names></name><name><surname>Haas</surname> <given-names>AJ</given-names></name><name><surname>Vepa</surname> <given-names>Y</given-names></name><name><surname>Lindqvist</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Thomas</surname> <given-names>PM</given-names></name><name><surname>Brundin</surname> <given-names>P</given-names></name><name><surname>Brundin</surname> <given-names>L</given-names></name><name><surname>Labrie</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The vermiform appendix impacts the risk of developing Parkinson's disease</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaar5280</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aar5280</pub-id><pub-id pub-id-type="pmid">30381408</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>C</given-names></name><name><surname>Rockenstein</surname> <given-names>E</given-names></name><name><surname>Spencer</surname> <given-names>B</given-names></name><name><surname>Kim</surname> <given-names>HK</given-names></name><name><surname>Adame</surname> <given-names>A</given-names></name><name><surname>Trejo</surname> <given-names>M</given-names></name><name><surname>Stafa</surname> <given-names>K</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Masliah</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Antagonizing neuronal Toll-like receptor 2 prevents synucleinopathy by activating autophagy</article-title><source>Cell Reports</source><volume>13</volume><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.044</pub-id><pub-id pub-id-type="pmid">26489461</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>C</given-names></name><name><surname>Spencer</surname> <given-names>B</given-names></name><name><surname>Rockenstein</surname> <given-names>E</given-names></name><name><surname>Yamakado</surname> <given-names>H</given-names></name><name><surname>Mante</surname> <given-names>M</given-names></name><name><surname>Adame</surname> <given-names>A</given-names></name><name><surname>Fields</surname> <given-names>JA</given-names></name><name><surname>Masliah</surname> <given-names>D</given-names></name><name><surname>Iba</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Rissman</surname> <given-names>RA</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Masliah</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation</article-title><source>Molecular Neurodegeneration</source><volume>13</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-018-0276-2</pub-id><pub-id pub-id-type="pmid">30092810</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Kwon</surname> <given-names>SH</given-names></name><name><surname>Kam</surname> <given-names>TI</given-names></name><name><surname>Panicker</surname> <given-names>N</given-names></name><name><surname>Karuppagounder</surname> <given-names>SS</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Kim</surname> <given-names>WR</given-names></name><name><surname>Kook</surname> <given-names>M</given-names></name><name><surname>Foss</surname> <given-names>CA</given-names></name><name><surname>Shen</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Kulkarni</surname> <given-names>S</given-names></name><name><surname>Pasricha</surname> <given-names>PJ</given-names></name><name><surname>Lee</surname> <given-names>G</given-names></name><name><surname>Pomper</surname> <given-names>MG</given-names></name><name><surname>Dawson</surname> <given-names>VL</given-names></name><name><surname>Dawson</surname> <given-names>TM</given-names></name><name><surname>Ko</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transneuronal propagation of pathologic α-Synuclein from the gut to the brain models Parkinson's Disease</article-title><source>Neuron</source><volume>103</volume><fpage>627</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.05.035</pub-id><pub-id pub-id-type="pmid">31255487</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname> <given-names>Y</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Hosoda</surname> <given-names>W</given-names></name><name><surname>Sen</surname> <given-names>JM</given-names></name><name><surname>Mattson</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chronic mild gut inflammation accelerates brain neuropathology and motor dysfunction in α-Synuclein mutant mice</article-title><source>NeuroMolecular Medicine</source><volume>21</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1007/s12017-019-08539-5</pub-id><pub-id pub-id-type="pmid">31079293</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname> <given-names>HA</given-names></name><name><surname>Wu</surname> <given-names>N</given-names></name><name><surname>Cely</surname> <given-names>I</given-names></name><name><surname>Kelly</surname> <given-names>RL</given-names></name><name><surname>Hean</surname> <given-names>S</given-names></name><name><surname>Richter</surname> <given-names>F</given-names></name><name><surname>Magen</surname> <given-names>I</given-names></name><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>Ackerson</surname> <given-names>LC</given-names></name><name><surname>Walwyn</surname> <given-names>W</given-names></name><name><surname>Masliah</surname> <given-names>E</given-names></name><name><surname>Chesselet</surname> <given-names>M-F</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name><name><surname>Maidment</surname> <given-names>NT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein</article-title><source>Journal of Neuroscience Research</source><volume>89</volume><fpage>1091</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1002/jnr.22611</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname> <given-names>JD</given-names></name><name><surname>Lee</surname> <given-names>MJ</given-names></name><name><surname>Lu</surname> <given-names>H</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Hong</surname> <given-names>JJ</given-names></name><name><surname>Seril</surname> <given-names>DN</given-names></name><name><surname>Sturgill</surname> <given-names>MG</given-names></name><name><surname>Yang</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice</article-title><source>The Journal of Nutrition</source><volume>133</volume><fpage>4172</fpage><lpage>4177</lpage><pub-id pub-id-type="doi">10.1093/jn/133.12.4172</pub-id><pub-id pub-id-type="pmid">14652367</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>YG</given-names></name><name><surname>Fang</surname> <given-names>D</given-names></name><name><surname>Le</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Epigallocatechin Gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury</article-title><source>Journal of Neuroscience Research</source><volume>78</volume><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1002/jnr.20315</pub-id><pub-id pub-id-type="pmid">15478178</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Liang</surname> <given-names>S</given-names></name><name><surname>Duan</surname> <given-names>Y</given-names></name><name><surname>Jin</surname> <given-names>F</given-names></name><name><surname>Qin</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural changes of gut Microbiota in Parkinson's disease and its correlation with clinical features</article-title><source>Science China Life Sciences</source><volume>60</volume><fpage>1223</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1007/s11427-016-9001-4</pub-id><pub-id pub-id-type="pmid">28536926</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>LC</given-names></name><name><surname>Wang</surname> <given-names>MN</given-names></name><name><surname>Tseng</surname> <given-names>TY</given-names></name><name><surname>Sung</surname> <given-names>JS</given-names></name><name><surname>Tsai</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution</article-title><source>Journal of Agricultural and Food Chemistry</source><volume>55</volume><fpage>1517</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1021/jf062816a</pub-id><pub-id pub-id-type="pmid">17256961</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>A</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Wei</surname> <given-names>X</given-names></name><name><surname>He</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Su</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gut Microbiota in patients with Parkinson's disease in southern China</article-title><source>Parkinsonism &amp; Related Disorders</source><volume>53</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.05.007</pub-id><pub-id pub-id-type="pmid">29776865</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Fang</surname> <given-names>F</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Tillander</surname> <given-names>A</given-names></name><name><surname>Ludvigsson</surname> <given-names>JF</given-names></name><name><surname>Ekbom</surname> <given-names>A</given-names></name><name><surname>Svenningsson</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Wirdefeldt</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Vagotomy and Parkinson disease: a swedish register-based matched-cohort study</article-title><source>Neurology</source><volume>88</volume><fpage>1996</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000003961</pub-id><pub-id pub-id-type="pmid">28446653</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundmark</surname> <given-names>K</given-names></name><name><surname>Westermark</surname> <given-names>GT</given-names></name><name><surname>Olsén</surname> <given-names>A</given-names></name><name><surname>Westermark</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: cross-seeding as a disease mechanism</article-title><source>PNAS</source><volume>102</volume><fpage>6098</fpage><lpage>6102</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501814102</pub-id><pub-id pub-id-type="pmid">15829582</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manfredsson</surname> <given-names>FP</given-names></name><name><surname>Luk</surname> <given-names>KC</given-names></name><name><surname>Benskey</surname> <given-names>MJ</given-names></name><name><surname>Gezer</surname> <given-names>A</given-names></name><name><surname>Garcia</surname> <given-names>J</given-names></name><name><surname>Kuhn</surname> <given-names>NC</given-names></name><name><surname>Sandoval</surname> <given-names>IM</given-names></name><name><surname>Patterson</surname> <given-names>JR</given-names></name><name><surname>O'Mara</surname> <given-names>A</given-names></name><name><surname>Yonkers</surname> <given-names>R</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology</article-title><source>Neurobiology of Disease</source><volume>112</volume><fpage>106</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.01.008</pub-id><pub-id pub-id-type="pmid">29341898</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matheoud</surname> <given-names>D</given-names></name><name><surname>Cannon</surname> <given-names>T</given-names></name><name><surname>Voisin</surname> <given-names>A</given-names></name><name><surname>Penttinen</surname> <given-names>AM</given-names></name><name><surname>Ramet</surname> <given-names>L</given-names></name><name><surname>Fahmy</surname> <given-names>AM</given-names></name><name><surname>Ducrot</surname> <given-names>C</given-names></name><name><surname>Laplante</surname> <given-names>A</given-names></name><name><surname>Bourque</surname> <given-names>MJ</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Cayrol</surname> <given-names>R</given-names></name><name><surname>Le Campion</surname> <given-names>A</given-names></name><name><surname>McBride</surname> <given-names>HM</given-names></name><name><surname>Gruenheid</surname> <given-names>S</given-names></name><name><surname>Trudeau</surname> <given-names>LE</given-names></name><name><surname>Desjardins</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intestinal infection triggers parkinson's disease-like symptoms in Pink1<sup>-/-</sup> mice</article-title><source>Nature</source><volume>571</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1405-y</pub-id><pub-id pub-id-type="pmid">31316206</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertsalmi</surname> <given-names>TH</given-names></name><name><surname>Aho</surname> <given-names>VTE</given-names></name><name><surname>Pereira</surname> <given-names>PAB</given-names></name><name><surname>Paulin</surname> <given-names>L</given-names></name><name><surname>Pekkonen</surname> <given-names>E</given-names></name><name><surname>Auvinen</surname> <given-names>P</given-names></name><name><surname>Scheperjans</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota</article-title><source>European Journal of Neurology</source><volume>24</volume><fpage>1375</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1111/ene.13398</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metsalu</surname> <given-names>T</given-names></name><name><surname>Vilo</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>W566</fpage><lpage>W570</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv468</pub-id><pub-id pub-id-type="pmid">25969447</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Pardo</surname> <given-names>P</given-names></name><name><surname>Dodiya</surname> <given-names>HB</given-names></name><name><surname>Engen</surname> <given-names>PA</given-names></name><name><surname>Forsyth</surname> <given-names>CB</given-names></name><name><surname>Huschens</surname> <given-names>AM</given-names></name><name><surname>Shaikh</surname> <given-names>M</given-names></name><name><surname>Voigt</surname> <given-names>RM</given-names></name><name><surname>Naqib</surname> <given-names>A</given-names></name><name><surname>Green</surname> <given-names>SJ</given-names></name><name><surname>Kordower</surname> <given-names>JH</given-names></name><name><surname>Shannon</surname> <given-names>KM</given-names></name><name><surname>Garssen</surname> <given-names>J</given-names></name><name><surname>Kraneveld</surname> <given-names>AD</given-names></name><name><surname>Keshavarzian</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of TLR4 in the gut-brain Axis in Parkinson's disease: a translational study from men to mice</article-title><source>Gut</source><volume>68</volume><fpage>829</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-316844</pub-id><pub-id pub-id-type="pmid">30554160</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perov</surname> <given-names>S</given-names></name><name><surname>Lidor</surname> <given-names>O</given-names></name><name><surname>Salinas</surname> <given-names>N</given-names></name><name><surname>Golan</surname> <given-names>N</given-names></name><name><surname>Tayeb-Fligelman</surname> <given-names>E</given-names></name><name><surname>Deshmukh</surname> <given-names>M</given-names></name><name><surname>Willbold</surname> <given-names>D</given-names></name><name><surname>Landau</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural insights into curli CsgA Cross-β fibril architecture inspire repurposing of Anti-amyloid compounds as Anti-biofilm agents</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007978</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007978</pub-id><pub-id pub-id-type="pmid">31469892</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname> <given-names>I</given-names></name><name><surname>Dubinsky</surname> <given-names>M</given-names></name><name><surname>Bressman</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>A</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Anti-Tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease</article-title><source>JAMA Neurology</source><volume>75</volume><fpage>939</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2018.0605</pub-id><pub-id pub-id-type="pmid">29710331</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poewe</surname> <given-names>W</given-names></name><name><surname>Seppi</surname> <given-names>K</given-names></name><name><surname>Tanner</surname> <given-names>CM</given-names></name><name><surname>Halliday</surname> <given-names>GM</given-names></name><name><surname>Brundin</surname> <given-names>P</given-names></name><name><surname>Volkmann</surname> <given-names>J</given-names></name><name><surname>Schrag</surname> <given-names>AE</given-names></name><name><surname>Lang</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Parkinson disease</article-title><source>Nature Reviews Disease Primers</source><volume>3</volume><elocation-id>17013</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id><pub-id pub-id-type="pmid">28332488</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimi</surname> <given-names>J</given-names></name><name><surname>Kovacs</surname> <given-names>GG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prevalence of mixed pathologies in the aging brain</article-title><source>Alzheimer's Research &amp; Therapy</source><volume>6</volume><elocation-id>82</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-014-0082-1</pub-id><pub-id pub-id-type="pmid">25419243</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritz</surname> <given-names>BR</given-names></name><name><surname>Paul</surname> <given-names>KC</given-names></name><name><surname>Bronstein</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Of pesticides and men: a California story of genes and environment in Parkinson's Disease</article-title><source>Current Environmental Health Reports</source><volume>3</volume><fpage>40</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s40572-016-0083-2</pub-id><pub-id pub-id-type="pmid">26857251</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockenstein</surname> <given-names>E</given-names></name><name><surname>Mallory</surname> <given-names>M</given-names></name><name><surname>Hashimoto</surname> <given-names>M</given-names></name><name><surname>Song</surname> <given-names>D</given-names></name><name><surname>Shults</surname> <given-names>CW</given-names></name><name><surname>Lang</surname> <given-names>I</given-names></name><name><surname>Masliah</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters</article-title><source>Journal of Neuroscience Research</source><volume>68</volume><fpage>568</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1002/jnr.10231</pub-id><pub-id pub-id-type="pmid">12111846</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakakibara</surname> <given-names>R</given-names></name><name><surname>Doi</surname> <given-names>H</given-names></name><name><surname>Fukudo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lewy Body constipation</article-title><source>Journal of the Anus, Rectum and Colon</source><volume>3</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.23922/jarc.2018-022</pub-id><pub-id pub-id-type="pmid">31559362</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname> <given-names>TR</given-names></name><name><surname>Debelius</surname> <given-names>JW</given-names></name><name><surname>Thron</surname> <given-names>T</given-names></name><name><surname>Janssen</surname> <given-names>S</given-names></name><name><surname>Shastri</surname> <given-names>GG</given-names></name><name><surname>Ilhan</surname> <given-names>ZE</given-names></name><name><surname>Challis</surname> <given-names>C</given-names></name><name><surname>Schretter</surname> <given-names>CE</given-names></name><name><surname>Rocha</surname> <given-names>S</given-names></name><name><surname>Gradinaru</surname> <given-names>V</given-names></name><name><surname>Chesselet</surname> <given-names>MF</given-names></name><name><surname>Keshavarzian</surname> <given-names>A</given-names></name><name><surname>Shannon</surname> <given-names>KM</given-names></name><name><surname>Krajmalnik-Brown</surname> <given-names>R</given-names></name><name><surname>Wittung-Stafshede</surname> <given-names>P</given-names></name><name><surname>Knight</surname> <given-names>R</given-names></name><name><surname>Mazmanian</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gut Microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's Disease</article-title><source>Cell</source><volume>167</volume><fpage>1469</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.018</pub-id><pub-id pub-id-type="pmid">27912057</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The impact of indigenous microbes on Parkinson's Disease</article-title><source>Neurobiology of Disease </source><volume>15</volume><elocation-id>104426</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2019.03.014</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheperjans</surname> <given-names>F</given-names></name><name><surname>Aho</surname> <given-names>V</given-names></name><name><surname>Pereira</surname> <given-names>PA</given-names></name><name><surname>Koskinen</surname> <given-names>K</given-names></name><name><surname>Paulin</surname> <given-names>L</given-names></name><name><surname>Pekkonen</surname> <given-names>E</given-names></name><name><surname>Haapaniemi</surname> <given-names>E</given-names></name><name><surname>Kaakkola</surname> <given-names>S</given-names></name><name><surname>Eerola-Rautio</surname> <given-names>J</given-names></name><name><surname>Pohja</surname> <given-names>M</given-names></name><name><surname>Kinnunen</surname> <given-names>E</given-names></name><name><surname>Murros</surname> <given-names>K</given-names></name><name><surname>Auvinen</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gut Microbiota are related to Parkinson's disease and clinical phenotype</article-title><source>Movement Disorders</source><volume>30</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1002/mds.26069</pub-id><pub-id pub-id-type="pmid">25476529</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname> <given-names>DO</given-names></name><name><surname>Mika</surname> <given-names>F</given-names></name><name><surname>Richter</surname> <given-names>AM</given-names></name><name><surname>Hengge</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The green tea polyphenol EGCG inhibits <italic>E. coli</italic> biofilm formation by impairing amyloid curli fibre assembly and downregulating the biofilm regulator CsgD via the σ(E) -dependent sRNA RybB</article-title><source>Molecular Microbiology</source><volume>101</volume><fpage>136</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1111/mmi.13379</pub-id><pub-id pub-id-type="pmid">26992034</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname> <given-names>F</given-names></name><name><surname>Stelzer</surname> <given-names>Y</given-names></name><name><surname>Shivalila</surname> <given-names>CS</given-names></name><name><surname>Abraham</surname> <given-names>BJ</given-names></name><name><surname>Latourelle</surname> <given-names>JC</given-names></name><name><surname>Barrasa</surname> <given-names>MI</given-names></name><name><surname>Goldmann</surname> <given-names>J</given-names></name><name><surname>Myers</surname> <given-names>RH</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression</article-title><source>Nature</source><volume>533</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/nature17939</pub-id><pub-id pub-id-type="pmid">27096366</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spires-Jones</surname> <given-names>TL</given-names></name><name><surname>Attems</surname> <given-names>J</given-names></name><name><surname>Thal</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interactions of pathological proteins in neurodegenerative diseases</article-title><source>Acta Neuropathologica</source><volume>134</volume><fpage>187</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1709-7</pub-id><pub-id pub-id-type="pmid">28401333</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>MF</given-names></name><name><surname>Zhu</surname> <given-names>YL</given-names></name><name><surname>Zhou</surname> <given-names>ZL</given-names></name><name><surname>Jia</surname> <given-names>XB</given-names></name><name><surname>Xu</surname> <given-names>YD</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Cui</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>YQ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Neuroprotective effects of fecal Microbiota transplantation on MPTP-induced parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway</article-title><source>Brain, Behavior, and Immunity</source><volume>70</volume><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2018.02.005</pub-id><pub-id pub-id-type="pmid">29471030</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname> <given-names>E</given-names></name><name><surname>Horváth-Puhó</surname> <given-names>E</given-names></name><name><surname>Thomsen</surname> <given-names>RW</given-names></name><name><surname>Djurhuus</surname> <given-names>JC</given-names></name><name><surname>Pedersen</surname> <given-names>L</given-names></name><name><surname>Borghammer</surname> <given-names>P</given-names></name><name><surname>Sørensen</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Vagotomy and subsequent risk of Parkinson's disease</article-title><source>Annals of Neurology</source><volume>78</volume><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1002/ana.24448</pub-id><pub-id pub-id-type="pmid">26031848</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tükel</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>RP</given-names></name><name><surname>Nishimori</surname> <given-names>JH</given-names></name><name><surname>Pezeshki</surname> <given-names>M</given-names></name><name><surname>Chromy</surname> <given-names>BA</given-names></name><name><surname>Bäumler</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Responses to amyloids of microbial and host origin are mediated through Toll-like receptor 2</article-title><source>Cell Host &amp; Microbe</source><volume>6</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.05.020</pub-id><pub-id pub-id-type="pmid">19616765</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tursi</surname> <given-names>SA</given-names></name><name><surname>Tükel</surname> <given-names>Çagla</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Curli-Containing enteric biofilms inside and out: matrix composition, immune recognition, and disease implications</article-title><source>Microbiology and Molecular Biology Reviews</source><volume>82</volume><elocation-id>00028-18</elocation-id><pub-id pub-id-type="doi">10.1128/MMBR.00028-18</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname> <given-names>N</given-names></name><name><surname>Yagi</surname> <given-names>H</given-names></name><name><surname>Uemura</surname> <given-names>MT</given-names></name><name><surname>Hatanaka</surname> <given-names>Y</given-names></name><name><surname>Yamakado</surname> <given-names>H</given-names></name><name><surname>Takahashi</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces lewy body-like aggregates in the brainstem via the vagus nerve</article-title><source>Molecular Neurodegeneration</source><volume>13</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-018-0257-5</pub-id><pub-id pub-id-type="pmid">29751824</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname> <given-names>MM</given-names></name><name><surname>Spiegel</surname> <given-names>J</given-names></name><name><surname>Dillmann</surname> <given-names>KU</given-names></name><name><surname>Grundmann</surname> <given-names>D</given-names></name><name><surname>Philippeit</surname> <given-names>H</given-names></name><name><surname>Bürmann</surname> <given-names>J</given-names></name><name><surname>Faßbender</surname> <given-names>K</given-names></name><name><surname>Schwiertz</surname> <given-names>A</given-names></name><name><surname>Schäfer</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Short chain fatty acids and gut Microbiota differ between patients with Parkinson's disease and age-matched controls</article-title><source>Parkinsonism &amp; Related Disorders</source><volume>32</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.08.019</pub-id><pub-id pub-id-type="pmid">27591074</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Berge</surname> <given-names>N</given-names></name><name><surname>Ferreira</surname> <given-names>N</given-names></name><name><surname>Gram</surname> <given-names>H</given-names></name><name><surname>Mikkelsen</surname> <given-names>TW</given-names></name><name><surname>Alstrup</surname> <given-names>AKO</given-names></name><name><surname>Casadei</surname> <given-names>N</given-names></name><name><surname>Tsung-Pin</surname> <given-names>P</given-names></name><name><surname>Riess</surname> <given-names>O</given-names></name><name><surname>Nyengaard</surname> <given-names>JR</given-names></name><name><surname>Tamgüney</surname> <given-names>G</given-names></name><name><surname>Jensen</surname> <given-names>PH</given-names></name><name><surname>Borghammer</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats</article-title><source>Acta Neuropathologica</source><volume>138</volume><fpage>535</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-02040-w</pub-id><pub-id pub-id-type="pmid">31254094</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbaan</surname> <given-names>D</given-names></name><name><surname>Marinus</surname> <given-names>J</given-names></name><name><surname>Visser</surname> <given-names>M</given-names></name><name><surname>van Rooden</surname> <given-names>SM</given-names></name><name><surname>Stiggelbout</surname> <given-names>AM</given-names></name><name><surname>van Hilten</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Patient-reported autonomic symptoms in parkinson disease</article-title><source>Neurology</source><volume>69</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000266593.50534.e8</pub-id><pub-id pub-id-type="pmid">17646625</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidakovic</surname> <given-names>L</given-names></name><name><surname>Singh</surname> <given-names>PK</given-names></name><name><surname>Hartmann</surname> <given-names>R</given-names></name><name><surname>Nadell</surname> <given-names>CD</given-names></name><name><surname>Drescher</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dynamic biofilm architecture confers individual and collective mechanisms of viral protection</article-title><source>Nature Microbiology</source><volume>3</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41564-017-0050-1</pub-id><pub-id pub-id-type="pmid">29085075</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname> <given-names>HE</given-names></name><name><surname>Yano</surname> <given-names>JM</given-names></name><name><surname>Fung</surname> <given-names>TC</given-names></name><name><surname>Hsiao</surname> <given-names>EY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The microbiome and host behavior</article-title><source>Annual Review of Neuroscience</source><volume>40</volume><fpage>21</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-072116-031347</pub-id><pub-id pub-id-type="pmid">28301775</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Magen</surname> <given-names>I</given-names></name><name><surname>Yuan</surname> <given-names>PQ</given-names></name><name><surname>Subramaniam</surname> <given-names>SR</given-names></name><name><surname>Richter</surname> <given-names>F</given-names></name><name><surname>Chesselet</surname> <given-names>MF</given-names></name><name><surname>Taché</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation</article-title><source>Neurogastroenterology &amp; Motility</source><volume>24</volume><fpage>e425</fpage><lpage>e436</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2012.01974.x</pub-id><pub-id pub-id-type="pmid">22779732</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Chapman</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sequence determinants of bacterial amyloid formation</article-title><source>Journal of Molecular Biology</source><volume>380</volume><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.05.019</pub-id><pub-id pub-id-type="pmid">18565345</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerman</surname> <given-names>AL</given-names></name><name><surname>Stöhr</surname> <given-names>J</given-names></name><name><surname>Aoyagi</surname> <given-names>A</given-names></name><name><surname>Rampersaud</surname> <given-names>R</given-names></name><name><surname>Krejciova</surname> <given-names>Z</given-names></name><name><surname>Watts</surname> <given-names>JC</given-names></name><name><surname>Ohyama</surname> <given-names>T</given-names></name><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Widjaja</surname> <given-names>K</given-names></name><name><surname>Oehler</surname> <given-names>A</given-names></name><name><surname>Sanders</surname> <given-names>DW</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name><name><surname>Seeley</surname> <given-names>WW</given-names></name><name><surname>Middleton</surname> <given-names>LT</given-names></name><name><surname>Gentleman</surname> <given-names>SM</given-names></name><name><surname>Mordes</surname> <given-names>DA</given-names></name><name><surname>Südhof</surname> <given-names>TC</given-names></name><name><surname>Giles</surname> <given-names>K</given-names></name><name><surname>Prusiner</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Propagation of prions causing synucleinopathies in cultured cells</article-title><source>PNAS</source><volume>112</volume><fpage>E4949</fpage><lpage>E4958</lpage><pub-id pub-id-type="doi">10.1073/pnas.1513426112</pub-id><pub-id pub-id-type="pmid">26286986</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Saur</surname> <given-names>T</given-names></name><name><surname>Duke</surname> <given-names>AN</given-names></name><name><surname>Grant</surname> <given-names>SG</given-names></name><name><surname>Platt</surname> <given-names>DM</given-names></name><name><surname>Rowlett</surname> <given-names>JK</given-names></name><name><surname>Isacson</surname> <given-names>O</given-names></name><name><surname>Yao</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95</article-title><source>Journal of Neurogenetics</source><volume>28</volume><fpage>98</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.3109/01677063.2014.892486</pub-id><pub-id pub-id-type="pmid">24702501</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Smith</surname> <given-names>DR</given-names></name><name><surname>Hufnagel</surname> <given-names>DA</given-names></name><name><surname>Chapman</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Experimental manipulation of the microbial functional amyloid called curli</article-title><source>Methods in Molecular Biology</source><volume>966</volume><fpage>53</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-245-2_4</pub-id><pub-id pub-id-type="pmid">23299728</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.53111.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Chiu</surname><given-names>Isaac M</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Desjardins</surname><given-names>Michel</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is an exciting study demonstrating how gut bacteria and associated curli proteins can promote α-synuclein aggregation and pathology both in the gut and in the brain that lead to behavioral deficits in mice. There is increasing interest in how the gut microbiome and pathogens can influence the spread and development of synucleinopathies such as Parkinson's disease. This study opens up questions of whether dysregulation of bacterial strains that produce curli or other similar proteins are associated with synucleinopathies in humans. Thank you for contributing your study.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Wendy Garrett as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Michel Desjardins (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this manuscript, Sampson et al. present evidence that bacteria in the gut can lead to the emergence of motor impairment in a PD-susceptible mouse model through the action of a bacterial amyloid protein. They examined whether a bacterially produced amyloid protein, curli, could contribute to the aggregation of mammalian αSyn, leading to PD-related neurological dysfunction. The manuscript is well written and concise. The authors used a &quot;reductionist&quot; approach and demonstrated that amyloid-producing bacteria induce PD-like symptoms in α-synuclein overexpressing mice (ASO). They then went on to show that the curli proteins (bacterial amyloid) has a similar effect when introduced in the gut. These data further support the emerging concept that peripheral events in the gut contributes to the pathophysiological process leading to PD. The study is well focused and built around complimentary sets of experiments with microorganisms and their protein products. Behavioral analyses, as well as characterization of the modification of dopaminergic neurons in the brain are provided. Their data indicates that motor impairment can occur without a significant loss of TH neurons in the substantia nigra but a decrease of dopamine in the striatum (as shown in a recent article by Matheoud et al., 2019). Finally, they used epigallocatechin gallate (EGCG) to block curli's ability to form biofilms and found that it blocked CsgA- accelerated αSyn formation.</p><p>All reviewers were overall enthusiastic about the findings presented in this study. However, they agree that it would be important for the authors to show that the motor impairment in their model can be reversed by L-DOPA treatment. Better clarity also about presented data (immunoblots, ENS analysis) would strengthen the manuscript.</p><p>Essential revisions:</p><p>1) If the behavioral findings are due to exacerbation of PD-like motor phenotype as the authors propose, then the authors should be able provide behavioral data showing that L-DOPA alleviates or reduces the behavioral abnormalities.</p><p>2) There seems to be a paucity of pathologic αSyn in TH neurons and the biochemical evidence is weak. It would help if the authors showed their full-length immunoblots of αSyn from the soluble versus insoluble fractions.</p><p>3) For neuropathology in the gut, can there be quantitative analysis of enteric neurons? The myenteric plexus was stained for α-synuclein and PGP9.5, but the numbers of enteric neurons were not quantified. Is there loss of neurons in the proximal large intestine?</p><p>4) A better explanation of how curli exacerbates the motor phenotype would help. Is it through enhancing inflammation, affecting DA metabolism or affecting other areas that express high levels of α-synuclein in these transgenic mice? Is there a correlation between aggregate burden or inflammation and behavior?</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Wendy Garrett (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>All reviewers agree that improvements have been made including additional data for quantification of neurons in the gut myenteric plexus, and revisions to the text.</p><p>However, there is a major point that must be addressed with necessary revisions to the text to tone down the relevance of their animal model and findings in relation to PD given the inability to reverse the phenotype with L-DOPA in this model (Point #1). An additional point is raised concerning the full immunoblot (Point #2).</p><p>1) The authors cited prior published work that the behavioral deficits in the Thy1-αSyn mice are not responsive to L-DOPA and as such argue that this experiment will not provide useful information. While we agree with the authors that in light of these prior published works, L-DOPA experiments are not likely to provide useful information. However, the fact that L-DOPA does not have an effect on the Thy1-αSyn mice indicates that the authors' claims that behavioral findings are due to exacerbation of PD-like motor phenotypes is specious. Since L-DOPA does not rescue the phenotype, while we understand their arguments, this animal model is not reflective of PD. Yet the authors continue to make statements throughout the revised paper that the motor deficits are consistent with the hallmarks of PD. For instance, the Abstract states &quot;<italic>Escherichia coli</italic> exacerbates hallmark disease features such as motor impairment and αSyn pathology in the gut and brain.&quot;</p><p>The authors need to therefore take a more balanced approach and present the Thy1-αSyn mice as a model of αSyn pathophysiology with accompanying behavior deficits and they should not make claims regarding motor impairment and the link to PD. In other words, the Thy1-αSyn mice represent a model of αSyn induced behavioral abnormalities only and claims regarding PD should be removed from the paper.</p><p>2) We could not easily find the requested full immunoblot of soluble vs. insoluble α-synuclein fractionations. It's currently in an embedded tab of an excel file: is there a way to post this on the actual figure instead of as a source data file (Figure 1—figure supplement 2D)?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.53111.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) If the behavioral findings are due to exacerbation of PD-like motor phenotype as the authors propose, then the authors should be able provide behavioral data showing that L-DOPA alleviates or reduces the behavioral abnormalities.</p></disp-quote><p>In the Thy1-αSyn mouse model, loss of dopamine production and degeneration of dopaminergic neurons occurs at 14 months of age (Chesselet et al., 2012), which is significantly later than the appearance of motor dysfunction (2-4 months of age; Fleming et al., 2004), neuroinflammation (1 month of age; Watson et al., 2012), and non-motor symptoms (including gastrointestinal motility at 2-3 months of age; Wang et al., 2012). As described in our study and previous reports (Chesselet et al., 2012; Lam et al., 2011), there is no notable loss of striatal dopamine (Figure 1—figure supplement 2Q) or loss of tyrosine hydroxylase expression (Figure 1—figure supplement 2R) at the time points used throughout our work. Therefore, our data are in complete agreement with published literature for a lack of dopamine dependence at early stages of disease, strongly suggest that dopamine replacement therapy would not have benefits in mice at the ages tested. In fact, this experiment has been performed in SPF mice, which are somewhat different than our colonization paradigms, showing that L-DOPA treatment paradoxically results in slightly increased motor impairment in the Thy1-αSyn mouse model at early ages (Fleming et al., 2006). The reason for this previous observation still remains unknown.</p><p>While we are technically able to perform the L-DOPA treatment studies and had previously considered them, the experiment would take over 14 months to complete and we feel it would not provide useful information (based on the published data referenced above and our observations in Figure 1—figure supplement 2Q, R). Accordingly, we make no claims about the role dopamine on motor phenotypes, as the focus of our study is identification of a bacterial pathway that can promote αSyn aggregation and pathophysiology in Thy1-αSyn mice, rather than a better understanding of the mouse model itself.</p><p>Aggregation of αSyn is central to both Parkinson’s disease and the pathophysiology of this mouse model. Prior studies have modulated αSyn aggregation through small molecules in this mouse model and have demonstrated motor phenotypes can be limited when αSyn is inhibited (Richter et al., 2017; Wrasidlo et al., 2016), or enhanced when αSyn aggregation is accelerated in vivo (Pokrzywa et al., 2017). Exploring the molecular pathways into how aggregation leads to motor phenotypes would require a separate dedicated study.</p><p>We hope the referees and editors agree that the investment in time and effort for L-DOPA treatment experiments outweigh their expected value to the current study. We have done our best to not over-interpret our findings and have restricted discussion to results directly supported by data, namely the discovery that curli from the gut microbiome are sufficient to induce αSyn aggregation and motor phenotypes in the widely-used Thy1-αSyn model of synucleinopathy. In future studies, we plan to test whether curli play a role in other mouse models of disease.</p><disp-quote content-type="editor-comment"><p>2) There seems to be a paucity of pathologic αSyn in TH neurons and the biochemical evidence is weak. It would help if the authors showed their full-length immunoblots of αSyn from the soluble versus insoluble fractions.</p></disp-quote><p>We have included the requested full immunoblot of soluble vs. insoluble α-synuclein fractionations (Figure 1—figure supplement 2D) in Figure 1—source data 1. Thank you for this suggestion.</p><disp-quote content-type="editor-comment"><p>3) For neuropathology in the gut, can there be quantitative analysis of enteric neurons? The myenteric plexus was stained for α-synuclein and PGP9.5, but the numbers of enteric neurons were not quantified. Is there loss of neurons in the proximal large intestine?</p></disp-quote><p>This has been previously investigated, and the Thy1-αSyn mouse does not show degeneration of any neurons in the myenteric plexus (Wang et al., 2012). Similarly, in our hands, we do not observe striking differences in the number of neurons per ganglion in the myenteric plexus under these colonization conditions (new Figure 1—figure supplement 2M). We thank the referees for this suggestion.</p><disp-quote content-type="editor-comment"><p>4) A better explanation of how curli exacerbates the motor phenotype would help. Is it through enhancing inflammation or affecting DA metabolism or affecting other areas that express high levels of α-synuclein in these transgenic mice? Is there a correlation between aggregate burden or inflammation and behavior?</p></disp-quote><p>This is indeed a critical point and we have addressed the various ways curli may impact motor symptoms in the manuscript (through modulation of inflammation and/or through acceleration of αSyn aggregation), though disentangling the pathways downstream of curli-mediated αSyn aggregation is not trivial. It is important to consider that αSyn aggregates activate the same innate immune receptors as CsgA (Kim et al., 2013; Tukel et al., 2005), and that inflammation can increase the propensity of αSyn to aggregate (reviewed in Lema Tome et al., 2013). Therefore, αSyn amyloid formation and inflammatory processes are intrinsically linked, and likely both involved in the disease process in ways that are currently unknown for any Syn-based animal model.</p><p>We have carefully revised the text in the discussion to unambiguously state that our results do not distinguish between inflammatory or amyloid-mediated outcomes. Further, we are actively addressing this topic by generating new mouse lines lacking specific inflammatory, αSyn aggregation or dopamine pathways to explore how curli exacerbate motor phenotypes.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>[…]</p><p>However, there is a major point that must be addressed with necessary revisions to the text to tone down the relevance of their animal model and findings in relation to PD given the inability to reverse the phenotype with L-DOPA in this model (Point #1). An additional point is raised concerning the full immunoblot (Point #2). Please read below:</p><p>1) The authors cited prior published work that the behavioral deficits in the Thy1-αSyn mice are not responsive to L-DOPA and as such argue that this experiment will not provide useful information. While we agree with the authors that in light of these prior published works, L-DOPA experiments are not likely to provide useful information. However, the fact that L-DOPA does not have an effect on the Thy1-αSyn mice indicates that the authors' claims that behavioral findings are due to exacerbation of PD-like motor phenotypes is specious. Since L-DOPA does not rescue the phenotype, while we understand their arguments, this animal model is not reflective of PD. Yet the authors continue to make statements throughout the revised paper that the motor deficits are consistent with the hallmarks of PD. For instance, the Abstract states &quot;<italic>Escherichia coli</italic> exacerbates hallmark disease features such as motor impairment and αSyn pathology in the gut and brain.&quot; The authors need to therefore take a more balanced approach and present the Thy1-αSyn mice as a model of αSyn pathophysiology with accompanying behavior deficits and they should not make claims regarding motor impairment and the link to PD. In other words, the Thy1-αSyn mice represent a model of αSyn induced behavioral abnormalities only and claims regarding PD should be removed from the paper.</p></disp-quote><p>We appreciate the comments and agree that eliminating any extrapolation from the mouse model to Parkinson’s disease is appropriate, and have done so. However, it is important to consider that while L-DOPA responsiveness is a necessary component of PD, other pathological processes are occurring prior to- and concurrent with- loss of dopamine neurons (e.g., αSynaccumulation, mitochondrial dysfunction, impaired proteostasis). Thy1-αSynand other mouse models allow exploration into other synucleinopathy-associated pathologies.</p><p>Based on the editorial feedback, we have carefully revised the manuscript to present the mouse model in a more balanced fashion. Specifically, we have removed almost all mention of PD in the introduction and Results sections, and importantly no longer refer to the characteristics of Thy1-αSynmice as “PD-like”. Text previously focused on PD is now more broadly framed in the context of synucleinopathy and we discuss the mouse model as being relevant for understanding physiological impact of αSynaccumulation. The few instances where we retain mention of PD reflects the fact that there is simply much more research on PD and the gut microbiome than other related disorders. Accordingly, most if not all use of “PD” is confined to referencing published literature, mostly in the Discussion section, while being careful to not give the impression that we are modeling PD in our study.</p><disp-quote content-type="editor-comment"><p>2) We could not easily find the requested full immunoblot of soluble vs. insoluble α-synuclein fractionations. It's currently in an embedded tab of an excel file: is there a way to post this on the actual figure instead of as a source data file (Figure 1—figure supplement 2D)?</p></disp-quote><p>We have added text to the figure legend to state explicitly that full length immunoblots are available in the associated source data file, as it would take considerable effort to reformat an existing figure. If the manuscript is accepted, the source data files are easily accessed with a hyperlink for each figure in the formatted text.</p></body></sub-article></article>